US20100105693A1 - Modulators of Muscarinic Receptors - Google Patents

Modulators of Muscarinic Receptors Download PDF

Info

Publication number
US20100105693A1
US20100105693A1 US12/652,357 US65235710A US2010105693A1 US 20100105693 A1 US20100105693 A1 US 20100105693A1 US 65235710 A US65235710 A US 65235710A US 2010105693 A1 US2010105693 A1 US 2010105693A1
Authority
US
United States
Prior art keywords
piperazin
bicyclo
pyridyl
hept
enylmethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/652,357
Inventor
Lewis Makings
Dennis Hurley
Miguel Gracia-Guzman Blanco
Daniele Bergeron
Akiko Nakatani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Priority to US12/652,357 priority Critical patent/US20100105693A1/en
Publication of US20100105693A1 publication Critical patent/US20100105693A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system

Definitions

  • the present invention relates to modulators of muscarinic receptors.
  • the present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.
  • the neurotransmitter acetylcholine binds to two types of cholinergic receptors: the ionotropic family of nicotinic receptors and the metabotropic family of muscarinic receptors.
  • Muscarinic receptors belong to the large superfamily of plasma membrane-bound G protein coupled receptors (GPCRs). To date, five subtypes of muscarinic receptors (M 1 -M 5 ) have been cloned and sequenced from a variety of species, and show a remarkably high degree of homology across species and receptor subtype.
  • M 1 -M 5 muscarinic receptors are predominantly expressed within the parasympathetic nervous system which exerts excitatory and inhibitory control over the central and peripheral tissues and participate in a number of physiologic functions, including heart rate, arousal, cognition, sensory processing, and motor control.
  • Muscarinic agonists such as muscarine and pilocarpine
  • antagonists such as atropine
  • atropine have been known for over a century, but little progress has been made in the discovery of receptor subtype-selective compounds, thereby making it difficult to assign specific functions to the individual receptors. See, e.g., DeLapp, N. et al., “Therapeutic Opportunities for Muscarinic Receptors in the Central Nervous System,” J. Med. Chem., 43 (23), pp. 4333-4353 (2000); Hulme, E. C. et al., “Muscarinic Receptor Subtypes,” Ann. Rev. Pharmacol. Toxicol., 30, pp.
  • the Muscarinic family of receptors is the target of a large number of pharmacological agents used for various diseases, including leading drugs for COPD, asthma, urinary incontinence, glaucoma, Alzheimer's (AchE inhibitors), and Pain.
  • Acute pain serves an important protective function in keeping the organism safe from stimuli that may produce tissue damage. Severe thermal, mechanical, or chemical inputs have the potential to cause severe damage to the organism if unheeded.
  • Acute pain serves to quickly remove the individual from the damaging environment. Acute pain by its very nature generally is short lasting and intense. Inflammatory pain on the other had may last for much longer periods of time and it's intensity is more graded. Inflammation may occur for many reasons including tissue damage, autoimmune response, and pathogen invasion.
  • Inflammatory pain is mediated by an “inflammatory soup” that consists of substance P, histamines, acid, prostaglandin, bradykinin, CGRP, cytokines, ATP, and neurotransmitter release.
  • the third class of pain is neuropathic and involves nerve damage that results in reorganization of neuronal proteins and circuits yielding a pathologic “sensitized” state that can produce chronic pain lasting for years. This type of pain provides no adaptive benefit and is particularly difficult to treat with existing therapies.
  • Pain, particularly neuropathic and intractable pain is a large unmet medical need. Millions of individuals suffer from severe pain that is not well controlled by current therapeutics.
  • the current drugs used to treat pain include NSAIDS, COX2 inhibitors, opioids, tricyclic antidepressants, and anticonvulsants.
  • Neuropathic pain has been particularly difficult to treat as it does not respond well to opiods until high doses are reached.
  • Gabapentin is currently the favored therapeutic for the treatment of neuropathic pain although it works in only 60% of patients where it shows modest efficacy. The drug is however very safe and side effects are generally tolerable although sedation is an issue at higher doses.
  • cholinergic drugs are limited by the lack of selectivity of these agents, with significant activation of the parasympathetic autonomous system and elevated incidence of adverse effects.
  • the molecular cloning of the muscarinic receptors and the identification of the physiological role of specific isoforms using knock-out mice, has recently delineated novel opportunities for selective muscarinic ligands, and has helped to define the selectivity profile that is required for enhanced efficacy and reduced side effects.
  • the present invention provides compounds of formula (I) useful in modulating activity of a muscarinic receptor:
  • V, G, x and A are defined herein.
  • the present invention also provides compositions comprising compounds of formula (I), and methods of treating muscarinic receptor mediated diseases using compounds of formula (I).
  • muscle receptor refers to one or more of the five receptor subtypes M 1 -M 5 .
  • modulating means increasing or decreasing, e.g. activity, by a measurable amount.
  • Compounds that modulate muscarinic activity by increasing the activity of the muscarinic receptors are called agonists.
  • Compounds that modulate muscarinic activity by decreasing the activity of the muscarinic receptors are called antagonists.
  • An agonist interacts with a muscarinic receptor to increase the ability of the receptor to transduce an intracellular signal in response to endogenous ligand binding.
  • An antagonist interacts with a muscarinic receptor and competes with the endogenous ligand(s) or substrate(s) for binding site(s) on the receptor to decrease the ability of the receptor to transduce an intracellular signal in response to endogenous ligand binding.
  • a muscarinic receptor mediated disease refers both to treatments for diseases that are directly caused by muscarinic activities and alleviation of symptoms of diseases not directly caused by muscarinic activities.
  • diseases whose symptoms may be affected by muscarinic activity include, but are not limited to, CNS derived pathologies including cognitive disorders, Attention Deficit Hyperactivity Disorder (ADHD), obesity, Alzheimer's disease, various dementias such as vascular dementia, psychosis including schizophrenia, mania, bipolar disorders, pain conditions including acute and chronic syndromes, Huntington's Chorea, Friederich's ataxia, Gilles de la Tourette's Syndrome, Downs Syndrome, Pick disease, clinical depression, Parkinson's disease, peripheral disorders such as reduction of intra ocular pressure in Glaucoma and treatment of dry eyes and dry mouth including Sjögren's Syndrome, bradhycardia, gastric acid secretion, asthma, GI disturbances and wound healing.
  • ADHD Attention Deficit Hyperactivity Disorder
  • obesity Alzheimer's disease
  • various dementias such
  • an optionally substituted group may have a substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position.
  • substituents envisioned by this invention are those combinations that result in the formation of stable or chemically feasible compounds.
  • aliphatic or “aliphatic group”, as used herein, means a straight-chain or branched, substituted or unsubstituted hydrocarbon chain that is completely saturated (alkyl) or is unsaturated (alkenyl or alkynyl). Unless otherwise specified, an aliphatic group has 1 to 12 carbon atoms, preferably, 1-6 carbon atoms, and more preferably, 1-4 carbon atoms. Up to three, and preferably two, CH 2 — in said aliphatic may be replaced with O, S, or —NR.
  • cycloaliphatic means a saturated or partially unsaturated monocyclic or bicyclic hydrocarbon ring that has a single point of attachment to the rest of the molecule.
  • preferred cycloaliphatic rings are 3-8 membered monocyclic rings, more preferably 3-6, and even more preferably, 3, 5, or 6.
  • 8-12 membered bicyclic hydrocarbon rings are also preferred, unless otherwise specified, are 8-12 membered bicyclic hydrocarbon rings, more preferably 10 membered bicyclic hydrocarbon rings.
  • heteroatom means nitrogen, oxygen, or sulfur and includes any oxidized form of nitrogen and sulfur, and the quaternized form of any basic nitrogen.
  • nitrogen includes a substitutable nitrogen of a heterocyclic ring.
  • the nitrogen in a saturated or partially unsaturated ring having 0-3 heteroatoms selected from oxygen, sulfur or nitrogen, the nitrogen may be N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or as in N-substituted pyrrolidinyl.
  • unsaturated means a double bond or a triple bond. Each such bond constitutes one unit of unsaturation.
  • aryl used alone or as part of a larger moiety as in “aralkyl”, “aralkoxy”, or “aryloxyalkyl”, refers to monocyclic, bicyclic and tricyclic aromatic carbocyclic ring systems. Unless otherwise specified, preferred aryl rings have a total of five to fourteen ring members, wherein at least one ring, if bicyclic or tricyclic, in the system is aromatic and wherein each ring in the system contains up to 6 ring members.
  • aryl may be used interchangeably with the term “aryl ring”. Phenyl is an example of aryl.
  • heterocycle means non-aromatic, monocyclic, bicyclic or tricyclic ring systems wherein one or more ring members is a heteroatom. Unless otherwise specified, each ring in the system preferably contains contains 3 to 7 ring members with preferably 1-3 heteroatoms.
  • heteroaryl used alone or as part of a larger moiety as in “heteroaralkyl” or “heteroarylalkoxy”, refers to monocyclic, bicyclic and tricyclic ring systems, wherein at least one ring in the system is aromatic, and at least one ring in the system contains one or more heteroatoms. Unless otherwise specified, such ring systems preferably have a total of 5 to 15 ring members, wherein each ring in the system preferably contains 3 to 7 ring members, with preferably 1-3 heteroatoms.
  • heteroaryl may be used interchangeably with the term “heteroaryl ring” or the term “heteroaromatic”.
  • a combination of substituents or variables is permissible only if such a combination results in a stable or chemically feasible compound.
  • a stable compound or chemically feasible compound is one that is not substantially altered when kept at a temperature of 40° C. or less, in the absence of moisture or other chemically reactive conditions, for at least a week.
  • protecting group refers to organic substituents used to protect a chemical functionality from reacting with reagents and reactants during chemical synthesis.
  • Various “protecting groups” are known. See, e.g., T. W. Greene & P. G. M Wutz, “Protective Groups in Organic Synthesis,” 3 rd Edition, John Wiley & Sons, Inc. (1999) along with any other editions of this book.
  • structures depicted herein are also meant to include all stereochemical forms of the structure including, e.g., endo, exo, R and S configurations. Therefore, single stereochemical isomers as well as enantiomeric and diastereomeric mixtures of the present compounds are within the scope of the invention.
  • structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of a hydrogen atom by a deuterium or tritium, or the replacement of a carbon by a 13 C— or 14 C-enriched carbon are within the scope of this invention. Such compounds are useful, for example, as analytical tools or probes in biological assays.
  • the present invention provides compounds of formula (I) useful in modulating activity of a muscarinic receptor:
  • V is a 5-6 membered unsaturated, monocyclic, heterocyclic ring containing 1-4 ring heteroatoms selected from O, S, and N, or a 5-15 membered heteroaromatic ring containing 1-4 ring heteroatoms selected from O, S, and N, in which the 5-6 membered unsaturated, monocyclic, heterocyclic ring and the 5-15 membered heteroaromatic ring are optionally substituted with 1 to 3 substituents selected from R 1 , R 2 , R 3 , R 4 , or R 5 ;
  • G is N or CR x ;
  • R x is H, halo, CN, R 2 , OR 6 , —(CH 2 ) w OC(O)R 2 , C(O)OR 2 , C(O)NH 2 , C(O)NHR 2 , or C(O)N(R 2 ) 2 ;
  • A is selected from:
  • A is adamantyl or adamantylmethyl
  • bond r is a single or double bond
  • each of X 1 , X 3 and X 4 is independently selected from CH 2 , CH 2 —CH 2 , O, S, SO 2 , NR, wherein R is R 2 or R 4 ;
  • X 2 is CH
  • each of W 1 , W 3 , and W 4 is independently selected from a bond, —(CH 2 ) i —, —(CH 2 ) i NR i C(O)—, —(CH 2 ) i C(O)NR i —, —(CH 2 ) i NR i SO 2 —, —(CH 2 ) i SO 2 NR i —, C(O), O, S, NH, or S(O) 2 ;
  • R i is H or R 2 ;
  • W 2 and X 2 taken together are selected from CH, CH 2 —CH, —(CH 2 ) i C(O)N—, or —(CH 2 ) i SO 2 N—;
  • ring B when present, is a 5-6 membered cycloaliphatic or 5-6 membered heterocyclic ring, in which the 5-6 membered cycloaliphatic or 5-6 membered heterocyclic ring are each optionally substituted with 1 to 3 substituents selected from R 1 , R 2 , R 3 , R 4 , or R 5 ;
  • R 1 is oxo or ((C1-C4)aliphatic) p -Y;
  • Y is halo, CN, NO 2 , CF 3 , OCF 3 , OH, SR 6 , S(O)R 6 , SO 2 R 6 , COOH, COOR 6 or OR 6 ; or
  • R 2 is aliphatic, wherein each R 2 optionally includes 1 to 2 substituents independently selected from R 1 , R 4 , or R 5 ;
  • R 3 is a cycloaliphatic, aryl, heterocyclic, or heteroaryl ring optionally including 1 to 3 substituents independently selected from R 1 , R 2 , R 4 , or R 5 ;
  • R 4 is OR 5 , OR 6 , S(O)R 6 , S(O)R 5 , SO 2 R 6 , SO 2 R 5 , SO 2 N(R 6 ) 2 , SO 2 N(R 5 ) 2 , SO 2 NR 5 R 6 , SO 3 R 6 , SO 3 R 5 , C(O)R 5 , C(O)OR 5 , C(O)R 6 , C(O)OR 6 , C(O)N(R 6 ) 2 , C(O)N(R 5 ) 2 , C(O)N(R 5 R 6 ), C(O)N(OR 6 )R 6 , C(O)N(OR 5 )R 6 , C(O)N(OR 5 )R 6 , C(O)N(OR 6 )R 5 , C(O)N(OR 5 )R 5 , C(NOR 6 )R 6 , C(NOR 6 )R 5 , C(NOR 5 )R 5 , NR
  • R 5 is a cycloaliphatic, aryl, heterocyclic, or heteroaryl ring, optionally including 1 to 3 R 1 substituents;
  • R 6 is H or aliphatic, wherein R 6 optionally includes a R 7 substituent;
  • R 7 is a cycloaliphatic, aryl, heterocyclic, or heteroaryl ring, and each R 7 optionally comprises up to 2 substituents independently chosen from H, (C 1 -C 6 )-straight or branched alkyl, (C 2 -C 6 ) straight or branched alkenyl or alkynyl, 1,2-methylenedioxy, 1,2-ethylenedioxy, or (CH 2 ) n —Z;
  • Each R 8 is selected from R 2 , R 3 , or R 4 or a protecting group.
  • Z is selected from halo, CN, NO 2 , CF 3 , OCF 3 , OH, S-aliphatic, S(O)-aliphatic, SO 2 -aliphatic, NH 2 , NH-aliphatic, N(aliphatic) 2 , COOH, C(O)O(-aliphatic), or O-aliphatic;
  • Each i is independently 1-3;
  • Each m is independently 1 or 2;
  • n is independently 0 or 1;
  • Each p is independently 0 or 1;
  • Each w is independently 0 or 1;
  • Each x is independently 1 or 2;
  • the present invention provides a compound having formula (II):
  • ring A II is selected from:
  • Each XX, YY, and Z 5 is independently CR′ or N;
  • Each XX 1 and YY 1 is independently selected from a bond, CH 2 , CHR 90 , O, S, NH, NR′, C(O), S(O), or SO 2 provided that both X 1 and Y 1 are not simultaneously a bond;
  • Each Z 6 is independently —C(R′) 2 —, —C(R′) 2 —C(R′) 2 —, —C(R′) 2 -Q-, or Q, wherein Q is O, —N(R′)—, —S(O)—, —SO 2 —, or —C(O)—;
  • Each Z 1 , Z 2 , Z 3 , and Z 4 is independently selected from CH 2 , CHR′, O, S, NH, NR′, C(O), S(O), SO 2 ;
  • Each R′ is independently selected from (C1-C4)aliphatic) mm -Q 1 , S(O) i R 60 , S(O) 8 R 50 , SO 2 N(R 60 ) 2 , SO 2 N(R 50 ) 2 , SO 2 NR 50 R 60 , C(O)R 50 , C(O)OR 50 , C(O)R 60 , C(O)OR 60 , C(O)N(R 60 ) 2 , C(O)N(R 50 ) 2 , C(O)N(R 50 R 60 ), C(O)N(OR 60 )R 60 , C(O)N(OR 50 )R 60 , C(O)N(OR 60 )R 50 , C(O)N(OR 50 )R 50 , C(O)N(OR 50 )R 50 , C(NOR 60 )R 60 , C(NOR 60 )R 50 , C(NOR 50 )R 60 , C(NOR 50 )R 50
  • Each R 10 is independently oxo or ((C1-C4)aliphatic) mm -Q 1 ;
  • Each Q 1 is independently halo, CN, NO 2 , CF 3 , OCF 3 , OH, SR 60 , S(O)R 60 , SO 2 R 60 , COOH, COOR 60 or OR 60 ;
  • Each R 20 is independently aliphatic optionally substituted with 1-3 substituents independently selected from R 10 , R 40 , or R 50 ;
  • Each R 30 is independently a cycloaliphatic, aryl, heterocyclic, or heteroaryl ring, wherein each of the cycloaliphatic, aryl, heterocyclic, or heteroaryl are optionally substituted with 1-3 substituents independently selected from R 10 , R 20 , R 40 ; or R 50 ;
  • Each R 40 is independently OR 50 , OR 60 , OC(O)R 60 , OC(O)R 50 , OC(O)OR 60 , OC(O)OR 50 , OC(O)N(R 60 ) 2 , OC(O)N(R 50 ) 2 , OC(O)N(R 60 R 50 ), S(O) i R 60 , S(O) i R 50 , SO 2 N(R 60 ) 2 , SO 2 N(R 50 ) 2 , SO 2 NR 50 R 60 , C(O)R 50 , C(O)OR 50 , C(O)R 60 , C(O)OR 60 , C(O)N(R 60 ) 2 , C(O)N(R 50 ) 2 , C(O)N(R 50 R 60 ), C(O)N(OR 60 )R 60 , C(O)N(OR 50 )R 60 , C(O)N(OR 60 )R 50 , C
  • Each R 50 is independently a cycloaliphatic, aryl, heterocyclic, or heteroaryl ring, wherein each of the cycloaliphatic, aryl, heterocyclic, or heteroaryl are optionally substituted with 1 to 3 of R 10 ;
  • Each R 60 is independently H or aliphatic optionally substituted with R 70 ;
  • Each R 70 is independently a cycloaliphatic, aryl, heterocyclic, or heteroaryl ring, wherein each of the cycloaliphatic, aryl, heterocyclic, or heteroaryl are optionally substituted with 1 to 2 of (C 1 -C 6 )-straight or branched alkyl, (C 2 -C 6 ) straight or branched alkenyl or alkynyl, 1,2-methylenedioxy, 1,2-ethylenedioxy, or (CH 2 ) nn -Q 2 ;
  • Each Q 2 is independently selected from halo, CN, NO 2 , CF 3 , OCF 3 , OH, S-aliphatic, S(O)-aliphatic, SO 2 -aliphatic, COOH, C(O)O-aliphatic, or O-aliphatic;
  • bond r is a single or double bond
  • Each R 80 is independently an amino protecting group
  • Each R 90 is independently R 2 , R 3 , or R 6 ;
  • Each ii is independently 0, 1, 2, or 3;
  • Each mm is independently 0 or 1;
  • nn is independently 0 or 1;
  • Each f is 0, 1 or 2;
  • Each g is 0, 1 or 2
  • the present invention provides compounds of formula (III):
  • r 0-3;
  • M is N or CH
  • E is a 3-6 membered unsaturated or aromatic, monocyclic, heterocyclic ring containing 1-3 ring nitrogen heteroatoms, or
  • E is optionally substituted with up to four substituents independently selected from R 1 , R 2 , R 3 , R 4 , or R 5 ;
  • D is N or CR′′
  • R′′ is H, halo, CN, R 2 , OR 6 , —(CH 2 ) w OC(O)R 2 , C(O)OR 2 , C(O)NH 2 , C(O)NHR 2 , or C(O)N(R 2 ) 2 ;
  • R′ is R 2 ;
  • x is 1 or 2;
  • the present invention provides compounds of formula (IV):
  • a IV is adamantanyl, adamantanylmethyl, or
  • Bond r is a single or double bond
  • Each X 1 is independently selected from CH 2 , CH 2 —CH 2 , or NR 400 ,
  • Each W 1 is independently selected from a bond, —(CH2) i —, —(CH 2 ) i NR i C(O)—, —(CH 2 ) i C(O)NR i —, —(CH 2 ) i NR i SO 2 —, —(CH 2 ) i SO 2 NR i —, C(O), O, S, NH, or S(O) 2 ;
  • R i is H or R 2 ;
  • R 2 is aliphatic, wherein each R 2 optionally includes 1 to 2 substituents independently selected from R 100 , R 4 , or R 5 ;
  • R 4 is OR 5 , OR 6 , S(O)R 6 , S(O)R 5 , SO 2 R 6 , SO 2 R 5 , SO 2 N(R 6 ) 2 , SO 2 N(R 5 ) 2 , SO 2 NR 5 R 6 , SO 3 R 6 , SO 3 R 5 , C(O)R 5 , C(O)OR 5 , C(O)R 6 , C(O)OR 6 , C(O)N(R 6 ) 2 , C(O)N(R 5 ) 2 , C(O)N(R 5 R 6 ), C(O)N(OR 6 )R 6 , C(O)N(OR 5 )R 6 , C(O)N(OR 5 )R 6 , C(O)N(OR 6 )R 5 , C(O)N(OR 5 )R 5 , C(NOR 6 )R 6 , C(NOR 6 )R 5 , C(NOR 5 )R 5 , NR
  • Each R 5 is independently a cycloaliphatic, aryl, heterocyclic, or heteroaryl ring, each optionally including 1 to 3 R 100 substituents;
  • Each R 6 is independently H or aliphatic optionally substituted with R 7 ;
  • Each R 7 is independently a cycloaliphatic, aryl, heterocyclic, or heteroaryl ring, each optionally substituted with up to 2 substituents independently selected from H, (C 1 -C 6 )-straight or branched alkyl, (C 2 -C 6 ) straight or branched alkenyl or alkynyl, 1,2-methylenedioxy, 1,2-ethylenedioxy, or (CH 2 ) n —Z;
  • Each R 8 is independently selected from R 2 , R 3 , or R 4 or a protecting group.
  • Each Z is independently selected from halo, —CN, —NO 2 , —CF 3 , —OCF 3 , —OH, —S-aliphatic, —S(O)-aliphatic, —SO 2 -aliphatic, —COOH, —C(O)O(-aliphatic), or —O-aliphatic;
  • G is N or C(H);
  • benzotriazole is optional substituted with 1-3 of R 100 , R2, R4, R5, or R6;
  • Each Z1 and Z3 is independently —N ⁇ , —C(H) ⁇ , or —C(R 100 ) ⁇ ;
  • Each Z2 is independently a carbon atom
  • Each Z4 and Z6 is independently —N ⁇ , —C(H) ⁇ or —C(R 100 ) ⁇ ;
  • Each Z5 is independently —N ⁇ , —C(H) ⁇ , or —C(R 200 ) ⁇ ,
  • Each R 100 is independently is —((C1-C4)aliphatic) p -Y2;
  • Y2 is halo, —CN, —NO 2 , —CF 3 , —OCF 3 , —SR 600 , —S(O)R 600 , —SO 2 R 600 , —SO 2 NR 600 , —COOR 600 , —C(O)N(R 600 ) 2 , or —OR 600 ; or
  • Each R 200 is independently R 100 or phenyl optionally substituted with 1-3 halo, —CN, —NO 2 , —CF 3 , —OCF 3 , —OH;
  • Each R 400 is independently OR 5 , OR 6 , S(O)R 6 , S(O)R 5 , SO 2 R 6 , SO 2 R 5 , SO 2 N(R 6 ) 2 , SO 2 N(R 5 ) 2 , SO 2 NR 5 R 6 , SO 3 R 6 , SO 3 R 5 , C(O)R 5 , C(O)OR 5 , C(O)R 6 , C(O)OR 6 , C(O)N(R 6 ) 2 , C(O)N(R 5 ) 2 , C(O)N(R 5 R 6 ), C(O)N(OR 6 )R 6 , C(O)N(OR 5 )R 6 , C(O)N(OR 6 )R 5 , C(O)N(OR 5 )R 5 , C(NOR 6 )R 6 , C(NOR 6 )R 5 , C(NOR 5 )R 6 , and C(NOR 5 )R 5 ;
  • Each R 600 is independently H or aliphatic optionally substituted with 1-3 substituents selected from halo, —CN, —NO 2 , —CF 3 , —OCF 3 , or —OH;
  • Each x is independently 1 or 2;
  • Each i is 0, 1 2, or 3;
  • Each m is independently 1 or 2;
  • Each p is independently 0 or 1;
  • Each w is independently 0 or 1;
  • V is not 2-(phenyl)-6-acetamidoethyl-amino-pyrimidin-4-yl or 2-(4-chlorophenyl)-6-acetamidoethyl-amino-pyrimidin-4-yl;
  • the compound is not 2-(4-bicyclo[2.2.1]hept-2-yl-1-piperazinyl)-pyrimidine or 2-[4-(bicyclo[2.2.1]hept-5-en-2-ylmethyl)-1-piperazinyl]-pyrimidine;
  • V is not 5-cyano-4-[(2,4-difluorophenyl)methyl]amino-2-pyrimidinyl, 5-ethoxycarbonyl-2-pyrimidinyl, or pyridine-2-yl-5-carboxylic acid.
  • Ring A is used interchangeably with Ring A II and Ring A IV .
  • A is selected from:
  • W 1 is as defined above.
  • A is (ia). Or, A is (ib). Or, A is (ic).
  • x is 1. Or, x is 2.
  • W 1 is a bond or CH 2 .
  • A is selected from:
  • W 2 is as defined above.
  • A is selected from (iia), (iib), or (iic). Or, A is (iia). Or, A is (iib). Or, A is (iic).
  • W 2 is a bond or CH 2 .
  • A is selected from:
  • W 3 is as defined above.
  • A is (iiia). Or, A is (iiib). Or, A is (iiic).
  • W 3 is a bond or CH 2 .
  • A is selected from:
  • W 4 is as defined above.
  • A is selected from:
  • W 4 is as defined above.
  • A is (iva). According to another embodiment, A is (ivb).
  • W 4 is a bond or CH 2 .
  • A is adamantyl or adamantylmethyl.
  • A is a
  • r, M and R′ are defined above in formula III.
  • r is 0.
  • r is 1.
  • r is 2.
  • M is CH.
  • M is N.
  • R′ is aliphatic.
  • R′ is alkyl.
  • R′ is methyl, ethyl, n-propyl, n-butyl, t-butyl, or isopropyl.
  • ring V is a six-membered aromatic ring containing 1-3 nitrogen ring atoms. According to one embodiment, ring V is a six-membered aromatic ring containing 1 nitrogen ring atom. According to another embodiment, ring V is a six-membered aromatic ring containing 2 nitrogen ring atoms. According to another embodiment, V is a 5-6 membered unsaturated, monocyclic, heterocyclic ring containing 1-4 ring heteroatoms selected from O, S, and N.
  • ring V or ring E is selected from optionally substituted:
  • each of the c-ring systems (a) through (k) is optionally substituted with 1 to 3 substituents selected from R 1 , R 2 , R 3 , R 4 , or R 5 .
  • ring V or ring E is
  • ring E is optionally substituted with up to four substituents independently selected from R 1 , R 2 , R 3 , R 4 , or R 5 .
  • ring V or ring E is
  • ring V or ring E is an optionally substituted pyridyl or pyrazinyl.
  • Preferred substituents on ring V or ring E include halo, cyano, C1-C4 alkyl, or CF 3 . More preferably, ring V or ring E is 3-cyano-2-pyridyl or 5-cyano-2-pyridyl.
  • ring V or ring E is contains up to 3 R 1 substituents, wherein each R 1 is independently as defined above. Or, ring V or ring E contains 1 or 2 R 1 substituents, wherein each R 1 is independently as defined herein. Ring V or ring E contains 1 to 3 of halo, cyano, C1-C4 alkyl, or CF 3 .
  • R 1 is R 6 , wherein R 6 is straight chain or branched (C1-C6)alkyl or (C2-C6 alkenyl) or alkynyl, optionally substituted with R 7 .
  • R 1 is (CH 2 ) m —Y, wherein m is 0, 1, or 2, and Y is halo, CN, NO 2 , CF 3 , OCF 3 , OH, SR 6 ,S(O)R 6 , SO 2 R 6 , COOH, COOR 6 or OR 6 .
  • R 1 is selected from halo, CF 3 , CN, NH 2 , NH(C1-C4 alkyl), NHC(O)CH 3 , OH, O(C1-C4 alkyl), OPh, O-benzyl, S—(C1-C4 alkyl), C1-C4 aliphatic, NO 2 , CN, methylenedioxy, ethylenedixoy, SO 2 NH(C1-C4 alkyl), or SO 2 N(C1-C4 alkyl) 2 .
  • R 1 is selected from methyl, n-propyl, i-propyl, t-butyl.
  • R 1 is selected from CN, halo, NO2, CF 3 , OCF 3 , or OH, preferably CN.
  • R 1 is selected from NH(CH 3 ), NHC(O)CH 3 , OCH 3 , OPh, O-benzyl, S—(C 2 H 5 ), S—CH 3 -methylenedioxy, SO 2 NH(n-propyl), or SO 2 N(n-propyl) 2 .
  • R 1 is selected from NHC(O)CH 3 , OCH 3 , OPh, O-benzyl, S—(C 2 H 5 ), S—CH 3 -methylenedioxy, SO 2 NH(n-propyl), or SO 2 N(n-propyl) 2 .
  • R 2 is a straight chain or branched (C1-C6)alkyl or (C2-C6) alkenyl or alkynyl, optionally substituted with R 1 , R 4 , or R 5 . More preferably, R 2 is a straight chain or branched (C1-C4)alkyl or (C2-C4) alkenyl or alkynyl, optionally substituted with R 1 , R 4 , or R 5 .
  • R 3 is optionally substituted phenyl, napthyl, C5-C10 heteroaryl or C 3 -C 7 heterocyclyl. More preferably, R 3 is an optionally substituted phenyl, C5-C6 heteroaryl, or C3-C6 heterocyclyl.
  • R 4 is selected from OR 5 or OR 6 .
  • R 5 is C5-C6 cycloalkyl, C6 or C10 aryl, C5-C10 heteroaryl or C3-C7 heterocyclyl, optionally substituted with up to 2 R 1 . More preferably, R 5 is an optionally substituted cyclohexyl, phenyl, C5-C6 heteroaryl, or C3-C6 heterocyclyl.
  • R 6 is H.
  • R 6 is a straight chain or branched (C1-C6)alkyl or (C2-C6 alkenyl) or alkynyl, optionally substituted with R 7 .
  • R 6 is a straight chain or branched (C1-C6)alkyl or (C2-C6 alkenyl) or alkynyl.
  • R 7 is C5-C6 cycloalkyl, phenyl, naphthyl, C5-C10 heteroaryl or C3-C7 heterocyclyl, optionally substituted with straight chain or branched (C1-C6)alkyl or (C2-C6 alkenyl) or alkynyl.
  • R 7 is C5-C6 cycloalkyl, phenyl, naphthyl, C5-C10 heteroaryl or C3-C7 heterocyclyl, optionally substituted with 1-2-methylenedioxy, 1,2-ethylenedioxy, or (CH 2 ) n —Z. More preferably, R 7 is an optionally substituted cyclohexyl, phenyl, C5-C6 heteroaryl, or C3-C6 heterocyclyl.
  • the compounds of formulae I and II do not include any additional basic nitrogen atoms other than those contained within the V ring, E ring, A ring, or the piperazine/piperidine ring.
  • the substituents, if any, on the V ring, E ring, A ring or the piperazine/piperidine ring do not include any basic nitrogen atoms, wherein a basic nitrogen atom is defined as any nitrogen whose conjugate acid pka is greater than 7.1.
  • the nitrogen atom at the 4 position relative to V is a basic nitrogen atom.
  • a and substituents attached to A do not include any basic nitrogen atoms, but V along with substituents attached to V may include one or more basic nitrogen atoms.
  • ring A does not include any basic nitrogen atoms that form ring A, such as the nitrogen in piperidine, but V and substituents attached to V and A may include one or more basic nitrogen atoms.
  • Examples of X include halogen, tosylate, mesylate and triflate.
  • Examples of a suitable functionality Y include an aldehyde or a ketone.
  • An example of a suitable reducing agent includes sodium triacetoxyborohydride.
  • An non-limiting example of a coupling catalyst is acetato(2′-di-t-butylphosphino-1,1′-biphenyl-2-yl)palladium (II).
  • the present invention includes within its scope pharmaceutically acceptable prodrugs of the compounds of the present invention.
  • a “pharmaceutically acceptable prodrug” means any pharmaceutically acceptable salt, ester, salt of an ester, or other derivative of a compound of the present invention which, upon administration to a recipient, is capable of providing (directly or indirectly) a compound of this invention or an active metabolite or residue thereof.
  • Preferred prodrugs are those that increase the bioavailability of the compounds of this invention when such compounds are administered to a mammal or which enhance delivery of the parent compound to a biological compartment relative to the parent species.
  • compositions of this invention refers to a non-toxic carrier, adjuvant, or vehicle that does not destroy the pharmacological activity of the compound with which it is formulated.
  • Pharmaceutically acceptable carriers, adjuvants or vehicles that may be used in the compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block
  • Pharmaceutically acceptable salts of the compounds of this invention include those derived from pharmaceutically acceptable inorganic and organic acids and bases.
  • suitable acid salts include acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptanoate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, palmoate, pec
  • Salts derived from appropriate bases include alkali metal (e.g., sodium and potassium), alkaline earth metal (e.g., magnesium), ammonium and N + (C 1-4 alkyl) 4 salts.
  • alkali metal e.g., sodium and potassium
  • alkaline earth metal e.g., magnesium
  • ammonium and N + (C 1-4 alkyl) 4 salts This invention also envisions the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. Water or oil-soluble or dispersible products may be obtained by such quaternization.
  • compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir.
  • parenteral as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques.
  • the compositions are administered orally, intraperitoneally or intravenously.
  • Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butanediol.
  • a non-toxic parenterally-acceptable diluent or solvent for example as a solution in 1,3-butanediol.
  • acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or di-glycerides.
  • Fatty acids such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions.
  • These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents that are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions.
  • Other commonly used surfactants such as Tweens, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.
  • compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions.
  • carriers commonly used include lactose and corn starch.
  • Lubricating agents such as magnesium stearate, are also typically added.
  • useful diluents include lactose and dried cornstarch.
  • aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.
  • compositions of this invention may be administered in the form of suppositories for rectal administration.
  • suppositories for rectal administration.
  • suppositories can be prepared by mixing the agent with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug.
  • suitable non-irritating excipient include cocoa butter, beeswax and polyethylene glycols.
  • compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.
  • Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-transdermal patches may also be used.
  • the pharmaceutically acceptable compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers.
  • Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water.
  • the pharmaceutically acceptable compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers.
  • Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
  • the pharmaceutically acceptable compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with or without a preservative such as benzylalkonium chloride.
  • the pharmaceutically acceptable compositions may be formulated in an ointment such as petrolatum.
  • compositions of this invention may also be administered by nasal aerosol or inhalation.
  • Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.
  • compositions of this invention are formulated for oral administration.
  • compositions should be formulated so that a dosage of between 0.01-100 mg/kg body weight/day of the modulator can be administered to a patient receiving these compositions.
  • a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated.
  • the amount of a compound of the present invention in the composition will also depend upon the particular compound in the composition.
  • additional therapeutic agents which are normally administered to treat or prevent that condition, may also be present in the compositions of this invention.
  • additional therapeutic agents that are normally administered to treat or prevent a particular disease, or condition are known as “appropriate for the disease, or condition, being treated.”
  • the compounds of formulae (I, II, III, and IV) are selective modulators of M 1 , M 2 and M 4 . More preferably, the compounds of formulae (I, II, III, and IV) are selective modulators of M 1 and/or M 4 . Yet more preferably, the compounds of formulae (I, II, III, and IV) are selective modulators of one of M 1 . Or, preferably, the compounds of formulae (I, II, III, and IV) are selective modulators of M 4 .
  • muscarinic receptors Applicants believe that the ability of the compounds of the present invention to modulate the activity of muscarinic receptors is derived from the affinity of these compounds to the muscarinic receptors. Such affinity, applicants believe, activates a muscarinic receptor (i.e, an agonist) or inhibits the activity of a muscarinic receptor.
  • the compounds of formula (I) are selective activators of M 1 , M 2 and M 4 . More preferably, these compounds are selective activators of M 1 and/or M 4 . Yet more preferably, the compounds of formula (I) are selective activators of M 1 . Or, preferably, the compounds of formula (I) are selective activators of M 4 .
  • the compounds of formula (II) are selective inhibitors of one or more of M 1 , M 2 , or M 4 .
  • the compounds of formula (II) are selective inhibitors of M 1 .
  • the compounds of formula (II) are selective inhibitors of M 4 .
  • the compounds of formula (III) are selective inhibitors of one or more of M 1 , M 2 , or M 4 .
  • the compounds of formula (III) are selective inhibitors of M 1 .
  • the compounds of formula (III) are selective inhibitors of M 4 .
  • the compounds of formula (IV) are selective inhibitors of one or more of M 1 , M 2 , or M 4 .
  • the compounds of formula (IV) are selective inhibitors of M 1 .
  • the compounds of formula (IV) are selective inhibitors of M 4 .
  • selective means a measurably greater ability to modulate one muscarinic receptor subtype when compared to the other muscarinic receptor subtypes.
  • selective M 4 agonist means a compound that has a measurably greater ability to act as an M 4 agonist when compared to that compound's agonist activity with the other muscarinic receptor subtype(s).
  • the present invention provides a method of treating a muscarinic receptor mediated disease in a mammal, comprising the step of administering to said mammal a composition comprising a compound of formula (I), or a preferred embodiment thereof as set forth above.
  • the present invention provides a method of treating a disease mediated by a muscarinic receptor comprising the step of administering to said mammal a composition comprising a compound of formula (I), or a preferred embodiment thereof as set forth above.
  • said disease is mediated by M 1 .
  • said disease is mediated by M 4 .
  • the present invention provides a method of treating or reducing the severity of a disease in a patient, wherein said disease is selected from CNS derived pathologies including cognitive disorders, Attention Deficit Hyperactivity Disorder (ADHD), obesity, Alzheimer's disease, various dementias such as vascular dementia, psychosis including schizophrenia, mania, bipolar disorders, pain conditions including acute and chronic syndromes, Huntington's Chorea, Friederich's ataxia, Gilles de la Tourette's Syndrome, Downs Syndrome, Pick disease, clinical depression, sudden infant death syndrome, Parkinson's disease, peripheral disorders such as reduction of intra ocular pressure in Glaucoma and treatment of dry eyes and dry mouth including Sjögren's Syndrome, wherein said method comprises the step of contacting said patient with a compound according to the present invention.
  • ADHD Attention Deficit Hyperactivity Disorder
  • various dementias such as vascular dementia, psychosis including schizophrenia, mania, bipolar disorders, pain conditions including acute and chronic syndromes, Huntington's Chorea, Friederich's ataxia, Gilles de
  • the present invention provides a method of treating or reducing the severity of a disease in a patient, wherein said disease is selected from pain, psychosis (including schizophrenia, hallucinations, and delusions), Alzheimer's disease, Parkinson's disease, glaucoma, bradhycardia, gastric acid secretion, asthma, or GI disturbances.
  • said disease is selected from pain, psychosis (including schizophrenia, hallucinations, and delusions), Alzheimer's disease, Parkinson's disease, glaucoma, bradhycardia, gastric acid secretion, asthma, or GI disturbances.
  • the present invention is useful for treating or reducing the severity of psychosis, Alzheimer's disease, pain, or Parkinson's disease.
  • reaction mixture was diluted with 1.0 mL DMSO:methanol (1:1), filtered and purified by reverse-phase HPLC (2-99% CH 3 CN in 0.085% TFA (aq), 50 mL/min, 2.0 mL injected).
  • CHO cells expressing muscarinic receptors are grown as monolayers in tissue culture flasks at 37° C. in a humidified atmosphere containing 5% CO 2 and passaged every 3-5 days.
  • the growth media is Dulbecco's modified eagles medium (DMEM, Gibco Cat# 12430-054), containing 25 mM Hepes and supplemented with Fetal Bovine Serum (Hyclone, cat# SH30071.03), 0.1 mM of MEM non-essential amino acids (GIBCO, Cat# 11140-050), 1 mM MEM Sodium Pyruvate (GIBCO Cat# 11360-070) and 100 units/ml of Penicillin G and 100 ⁇ g/ml of Streptomycin (GIBCO Cat# 15140-122).
  • the recombinant muscarinic receptor cell lines are grown under antibiotic pressure with media containing 25 ⁇ g/ml zeocin and 500 ⁇ g/ml G418 (M1-CHO), 4 ⁇ g/ml puromycin, 50 ⁇ g/ml zeocin and 2.5 ⁇ g/ml blasticidin (M2 and M4-CHO) or 50 ⁇ g/ml zeocin and 4 ⁇ g/ml puromycin (M3 and M5-CHO).
  • media containing 25 ⁇ g/ml zeocin and 500 ⁇ g/ml G418 (M1-CHO), 4 ⁇ g/ml puromycin, 50 ⁇ g/ml zeocin and 2.5 ⁇ g/ml blasticidin (M2 and M4-CHO) or 50 ⁇ g/ml zeocin and 4 ⁇ g/ml puromycin (M3 and M5-CHO).
  • the cells are washed with a plate washer (Bioteck Instruments, ELX 405) using bath1 buffer (140-mM NaCl, 4.5-mM KCl, 2-mM CaCl 2 , 1-mM MgCl 2 , 10-mM Hepes-Na, 10-mM Glucose, pH 7.4, with NaOH) containing 1 mM Probenecid.
  • bath1 buffer 140-mM NaCl, 4.5-mM KCl, 2-mM CaCl 2 , 1-mM MgCl 2 , 10-mM Hepes-Na, 10-mM Glucose, pH 7.4, with NaOH
  • the calcium dye Fluo-3 25 ⁇ l/well of Fluo-3 AM at 4 ⁇ M, Molecular Probes F-1241, in Bath 1 buffer containing 1 mM Probenecid
  • Bath 1 buffer containing 1 mM Probenecid is added to the 25 ⁇ l of Bath 1 remaining in each well after the plate wash and the dye is loaded at 37° C
  • cells can be loaded with the calcium indicator from Molecular Devices (Calcium 3 Assay Reagents, Cat # R7181) adding 5 ⁇ l of a 5 ⁇ solution dye in Bath 1 containing 1 mM Probenecid (10 ml per dye flask cat# R7182 to generate a solution 20 ⁇ ) to 20 ⁇ l of the same buffer. After loading for 60 min, the experiment can be run without having to remove the dye.
  • Compounds are prepared at a 2 ⁇ fold concentration in a 96-well plate (round bottom, Costar Corning cat# 3656), by reconstituting the pre-spotted compounds in bath 1 containing 1 mM probenecid.
  • the final concentration DMSO is 0.5%, and the amount of DMSO is normalized across the assay plate.
  • the reconstituted compounds are added (25 ⁇ l compound/well) to the cell assay plate (containing 25 ⁇ l/well) using the multi-channel robotic system of the FLIPR 3 Instrument (Molecular Devices, Sunnyvale, Calif.).
  • the reconstituted compounds are added (25 ⁇ l compound/well) to the assay plate and pre-incubated for 15 min prior to adding 25 ⁇ l of Carbachol at 3 ⁇ the EC80 for each muscarinic subtype.
  • the compounds can be co-applied simultaneously with the agonist.
  • the fluorescence is recorded for 60 sec (excitation wavelength is 488 nM and emission wavelength 540 nm) using the FLIPR 3 instrument.
  • the potency, efficacy and selectivity of the muscarinic compounds were evaluated by screening the compound activity across the whole family (M1 to M5 cells).
  • the compounds of the present invention were found to selectively modulate the muscarinic receptors selectively over the other receptor types.
  • muscarinic receptors M1 to M5
  • NFAT activation mediated by calcium release
  • the growth media is Dulbecco's modified eagles medium (DMEM, Gibco Cat# 12430-054), containing 25 mM Hepes and supplemented with 10% Fetal Bovine Serum (Hyclone, cat# SH30071.03), 0.1 mM of MEM non-essential amino acids (GIBCO, Cat# 11140-050), 1 mM MEM Sodium Pyruvate (GIBCO Cat# 11360-070) and 100 units/ml of Penicillin G and 100 ⁇ g/ml of Streptomycin (GIBCO Cat# 15140-122).
  • the recombinant muscarinic receptor cell lines are grown under antibiotic pressure with media containing 25 ⁇ g/ml zeocin and 500 ⁇ g/ml G418 (M1-CHO), 4 ⁇ g/ml puromycin, 50 ⁇ g/ml zeocin and 2.5 ⁇ g/ml blasticidin (M2 and M4-CHO) or 50 ⁇ g/ml zeocin and 4 ⁇ g/ml puromycin (M3 and M5-CHO).
  • media containing 25 ⁇ g/ml zeocin and 500 ⁇ g/ml G418 (M1-CHO), 4 ⁇ g/ml puromycin, 50 ⁇ g/ml zeocin and 2.5 ⁇ g/ml blasticidin (M2 and M4-CHO) or 50 ⁇ g/ml zeocin and 4 ⁇ g/ml puromycin (M3 and M5-CHO).
  • Cells are harvested at 80-90% confluence using Accutase (Innovative Cell Technologies, Inc. Cat# AT104), collected by centrifugation and seeded for 2-6 hours at a density of 15,000-20,000 cells/well in black-walled, clear-bottomed 384-well plates (BD Biocoat, poly-D-lysine, Cat#356663). Media is replaced with DMEM+1% Fetal Bovine Serum and incubated for another 12-18 hrs prior to running the ⁇ -Lactamase assay. The day of the experiment, compounds are prepared at a 1 ⁇ fold concentration in a 96-well plate (round bottom, Costar Corning cat# 3656), by reconstituting the pre-spotted compounds in DMEM+1% FBS.
  • the final concentration of DMSO is 0.5%, and the amount of DMSO is normalized across the assay plate.
  • the reconstituted compounds are added (25 ⁇ l compound/well) to the cell assay plate (where the media has been removed) using the multi-channel robotic system, Multimek 96 (Beckman). The compounds are incubated with the cells for 3 hours at 37° C., 5% CO 2 . to allow for expression of the reporter gene ⁇ -Lactamase.
  • the potency, efficacy and selectivity of the muscarinic compounds were evaluated by screening the compound activity across the whole family (M1 to M5 cells). Compounds were also screened for activity on other proteins such as other GPCRs and ion channels to determine selectivity on M4 receptors.
  • the compounds of the present invention were found to modulate the muscarinic receptors selectively over the other receptor types.
  • Table 3 contains activity data for the compounds listed in Tables 1 and 2.
  • the symbol “+++” refers to compounds which exhibited muscarinic modulation activity for at least one muscarinic receptor, M1, M2, M3, M4, at a concentration of less than 5 ⁇ M.
  • the symbol “++” refers to compounds which exhibited muscarinic modulation activity for at least one muscarinic receptor, M1, M2, M3, M4, at a concentration of between 30 ⁇ M and 5 ⁇ M.
  • the symbol “+” refers to compounds which exhibited muscarinic modulation activity for at least one muscarinic receptor, M1, M2, M3, M4, at a concentration of greater than 30 ⁇ M.
  • the symbol “ ⁇ ” refers to compounds which were not assayed or did not exhibit muscarinic modulation activity for at least one muscarinic receptor, M1, M2, M3, M4, at the concentration at which the assay was performed.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)

Abstract

The present invention relates to substituted piperazine compounds that are useful modulators of muscarinic receptors. The present invention also provides compositions comprising such compounds, and methods for treating muscarinic receptor mediated diseases.

Description

    CROSS-REFERENCE
  • This application is a divisional application, claiming priority under 35 U.S.C. §121 to U.S. application Ser. No. 11/140,808, filed on May 31, 2005, which claims priority under 35 U.S.C. §119(e) to U.S. Provisional application No. 60/575,233 filed on May 28, 2004. The entire contents of both applications are incorporated herein by reference.
    • TECHNICAL FIELD OF THE INVENTION
  • The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.
    • BACKGROUND OF THE INVENTION
  • The neurotransmitter acetylcholine binds to two types of cholinergic receptors: the ionotropic family of nicotinic receptors and the metabotropic family of muscarinic receptors. Muscarinic receptors belong to the large superfamily of plasma membrane-bound G protein coupled receptors (GPCRs). To date, five subtypes of muscarinic receptors (M1-M5) have been cloned and sequenced from a variety of species, and show a remarkably high degree of homology across species and receptor subtype. These M1-M5 muscarinic receptors are predominantly expressed within the parasympathetic nervous system which exerts excitatory and inhibitory control over the central and peripheral tissues and participate in a number of physiologic functions, including heart rate, arousal, cognition, sensory processing, and motor control.
  • Muscarinic agonists such as muscarine and pilocarpine, and antagonists, such as atropine have been known for over a century, but little progress has been made in the discovery of receptor subtype-selective compounds, thereby making it difficult to assign specific functions to the individual receptors. See, e.g., DeLapp, N. et al., “Therapeutic Opportunities for Muscarinic Receptors in the Central Nervous System,” J. Med. Chem., 43 (23), pp. 4333-4353 (2000); Hulme, E. C. et al., “Muscarinic Receptor Subtypes,” Ann. Rev. Pharmacol. Toxicol., 30, pp. 633-673 (1990); Caulfield, M. P. et al., “Muscarinic Receptors—Characterization, Coupling, and Function,” Pharmacol. Ther., 58, pp. 319-379 (1993); Caulfield, M. P. et al., International Union of Pharmacology. XVII. Classification of Muscarinic Acetylcholine Receptors,” Pharmacol. Rev., 50, pp. 279-290 (1998), the disclosures of which are incorporated herein by reference.
  • The Muscarinic family of receptors is the target of a large number of pharmacological agents used for various diseases, including leading drugs for COPD, asthma, urinary incontinence, glaucoma, Alzheimer's (AchE inhibitors), and Pain.
  • Pain can be roughly divided into three different types: acute, inflammatory, and neuropathic. Acute pain serves an important protective function in keeping the organism safe from stimuli that may produce tissue damage. Severe thermal, mechanical, or chemical inputs have the potential to cause severe damage to the organism if unheeded. Acute pain serves to quickly remove the individual from the damaging environment. Acute pain by its very nature generally is short lasting and intense. Inflammatory pain on the other had may last for much longer periods of time and it's intensity is more graded. Inflammation may occur for many reasons including tissue damage, autoimmune response, and pathogen invasion. Inflammatory pain is mediated by an “inflammatory soup” that consists of substance P, histamines, acid, prostaglandin, bradykinin, CGRP, cytokines, ATP, and neurotransmitter release. The third class of pain is neuropathic and involves nerve damage that results in reorganization of neuronal proteins and circuits yielding a pathologic “sensitized” state that can produce chronic pain lasting for years. This type of pain provides no adaptive benefit and is particularly difficult to treat with existing therapies.
  • Pain, particularly neuropathic and intractable pain is a large unmet medical need. Millions of individuals suffer from severe pain that is not well controlled by current therapeutics. The current drugs used to treat pain include NSAIDS, COX2 inhibitors, opioids, tricyclic antidepressants, and anticonvulsants. Neuropathic pain has been particularly difficult to treat as it does not respond well to opiods until high doses are reached. Gabapentin is currently the favored therapeutic for the treatment of neuropathic pain although it works in only 60% of patients where it shows modest efficacy. The drug is however very safe and side effects are generally tolerable although sedation is an issue at higher doses.
  • Despite the large therapeutic value of this family, cholinergic drugs are limited by the lack of selectivity of these agents, with significant activation of the parasympathetic autonomous system and elevated incidence of adverse effects. The molecular cloning of the muscarinic receptors and the identification of the physiological role of specific isoforms using knock-out mice, has recently delineated novel opportunities for selective muscarinic ligands, and has helped to define the selectivity profile that is required for enhanced efficacy and reduced side effects.
  • There is a need for modulators of muscarinic receptors M1-M5. There is also a need for methods for treating muscarinic receptor-mediated diseases.
  • There is also a need for modulators of muscarinic receptors that are selective as to subtypes M1-M5.
    • SUMMARY OF THE INVENTION
  • The present invention provides compounds of formula (I) useful in modulating activity of a muscarinic receptor:
  • Figure US20100105693A1-20100429-C00001
  • wherein V, G, x and A are defined herein.
  • The present invention also provides compositions comprising compounds of formula (I), and methods of treating muscarinic receptor mediated diseases using compounds of formula (I).
    • DETAILED DESCRIPTION OF THE INVENTION I. Definitions
  • As used herein, the following definitions shall apply unless otherwise indicated. For purposes of this invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th Ed. Additionally, general principles of organic chemistry are described in “Organic Chemistry”, Thomas Sorrell, University Science Books, Sausalito: 1999, and “March's Advanced Organic Chemistry”, 5th Ed., Ed.: Smith, M. B. and March, J., John Wiley & Sons, New York: 2001, the entire contents of which are hereby incorporated by reference.
  • The term “muscarinic receptor,” without a prefix specifying the receptor subtype, refers to one or more of the five receptor subtypes M1-M5.
  • The term “modulating” as used herein means increasing or decreasing, e.g. activity, by a measurable amount. Compounds that modulate muscarinic activity by increasing the activity of the muscarinic receptors are called agonists. Compounds that modulate muscarinic activity by decreasing the activity of the muscarinic receptors are called antagonists. An agonist interacts with a muscarinic receptor to increase the ability of the receptor to transduce an intracellular signal in response to endogenous ligand binding. An antagonist interacts with a muscarinic receptor and competes with the endogenous ligand(s) or substrate(s) for binding site(s) on the receptor to decrease the ability of the receptor to transduce an intracellular signal in response to endogenous ligand binding.
  • The phrase “treating or reducing the severity of a muscarinic receptor mediated disease” refers both to treatments for diseases that are directly caused by muscarinic activities and alleviation of symptoms of diseases not directly caused by muscarinic activities. Examples of diseases whose symptoms may be affected by muscarinic activity include, but are not limited to, CNS derived pathologies including cognitive disorders, Attention Deficit Hyperactivity Disorder (ADHD), obesity, Alzheimer's disease, various dementias such as vascular dementia, psychosis including schizophrenia, mania, bipolar disorders, pain conditions including acute and chronic syndromes, Huntington's Chorea, Friederich's ataxia, Gilles de la Tourette's Syndrome, Downs Syndrome, Pick disease, clinical depression, Parkinson's disease, peripheral disorders such as reduction of intra ocular pressure in Glaucoma and treatment of dry eyes and dry mouth including Sjögren's Syndrome, bradhycardia, gastric acid secretion, asthma, GI disturbances and wound healing.
  • The phrase “optionally substituted” is used interchangeably with the phrase “substituted or unsubstituted.” As described herein, compounds of the invention may optionally be substituted with one or more substituents, such as are illustrated generally above, or as exemplified by particular classes, subclasses, and species of the invention. It will be appreciated that the phrase “optionally substituted” is used interchangeably with the phrase “substituted or unsubstituted.” In general, the term “substituted”, whether preceded by the term “optionally” or not, refers to the replacement of hydrogen radicals in a given structure with the radical of a specified substituent. Unless otherwise indicated, an optionally substituted group may have a substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position. As one of ordinary skill in the art will recognize, combinations of substituents envisioned by this invention are those combinations that result in the formation of stable or chemically feasible compounds.
  • The term “aliphatic” or “aliphatic group”, as used herein, means a straight-chain or branched, substituted or unsubstituted hydrocarbon chain that is completely saturated (alkyl) or is unsaturated (alkenyl or alkynyl). Unless otherwise specified, an aliphatic group has 1 to 12 carbon atoms, preferably, 1-6 carbon atoms, and more preferably, 1-4 carbon atoms. Up to three, and preferably two, CH2— in said aliphatic may be replaced with O, S, or —NR.
  • The term “cycloaliphatic” means a saturated or partially unsaturated monocyclic or bicyclic hydrocarbon ring that has a single point of attachment to the rest of the molecule. Unless otherwise specified, preferred cycloaliphatic rings are 3-8 membered monocyclic rings, more preferably 3-6, and even more preferably, 3, 5, or 6. Also preferred, unless otherwise specified, are 8-12 membered bicyclic hydrocarbon rings, more preferably 10 membered bicyclic hydrocarbon rings.
  • The term “heteroatom,” unless otherwise specified, means nitrogen, oxygen, or sulfur and includes any oxidized form of nitrogen and sulfur, and the quaternized form of any basic nitrogen. Also the term “nitrogen” includes a substitutable nitrogen of a heterocyclic ring. As an example, in a saturated or partially unsaturated ring having 0-3 heteroatoms selected from oxygen, sulfur or nitrogen, the nitrogen may be N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or as in N-substituted pyrrolidinyl.
  • The term “unsaturated”, as used herein, means a double bond or a triple bond. Each such bond constitutes one unit of unsaturation.
  • The term “aryl” used alone or as part of a larger moiety as in “aralkyl”, “aralkoxy”, or “aryloxyalkyl”, refers to monocyclic, bicyclic and tricyclic aromatic carbocyclic ring systems. Unless otherwise specified, preferred aryl rings have a total of five to fourteen ring members, wherein at least one ring, if bicyclic or tricyclic, in the system is aromatic and wherein each ring in the system contains up to 6 ring members. The term “aryl” may be used interchangeably with the term “aryl ring”. Phenyl is an example of aryl.
  • The term in “heterocycle”, “heterocyclyl”, or “heterocyclic” as used herein means non-aromatic, monocyclic, bicyclic or tricyclic ring systems wherein one or more ring members is a heteroatom. Unless otherwise specified, each ring in the system preferably contains contains 3 to 7 ring members with preferably 1-3 heteroatoms.
  • The term “heteroaryl”, used alone or as part of a larger moiety as in “heteroaralkyl” or “heteroarylalkoxy”, refers to monocyclic, bicyclic and tricyclic ring systems, wherein at least one ring in the system is aromatic, and at least one ring in the system contains one or more heteroatoms. Unless otherwise specified, such ring systems preferably have a total of 5 to 15 ring members, wherein each ring in the system preferably contains 3 to 7 ring members, with preferably 1-3 heteroatoms. The term “heteroaryl” may be used interchangeably with the term “heteroaryl ring” or the term “heteroaromatic”.
  • A combination of substituents or variables is permissible only if such a combination results in a stable or chemically feasible compound. A stable compound or chemically feasible compound is one that is not substantially altered when kept at a temperature of 40° C. or less, in the absence of moisture or other chemically reactive conditions, for at least a week.
  • As used herein, the term “protecting group” refers to organic substituents used to protect a chemical functionality from reacting with reagents and reactants during chemical synthesis. Various “protecting groups” are known. See, e.g., T. W. Greene & P. G. M Wutz, “Protective Groups in Organic Synthesis,” 3rd Edition, John Wiley & Sons, Inc. (1999) along with any other editions of this book.
  • Unless otherwise stated, structures depicted herein are also meant to include all stereochemical forms of the structure including, e.g., endo, exo, R and S configurations. Therefore, single stereochemical isomers as well as enantiomeric and diastereomeric mixtures of the present compounds are within the scope of the invention. Unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of a hydrogen atom by a deuterium or tritium, or the replacement of a carbon by a 13C— or 14C-enriched carbon are within the scope of this invention. Such compounds are useful, for example, as analytical tools or probes in biological assays.
    • II. Compounds
  • The present invention provides compounds of formula (I) useful in modulating activity of a muscarinic receptor:
  • Figure US20100105693A1-20100429-C00002
  • wherein:
  • V is a 5-6 membered unsaturated, monocyclic, heterocyclic ring containing 1-4 ring heteroatoms selected from O, S, and N, or a 5-15 membered heteroaromatic ring containing 1-4 ring heteroatoms selected from O, S, and N, in which the 5-6 membered unsaturated, monocyclic, heterocyclic ring and the 5-15 membered heteroaromatic ring are optionally substituted with 1 to 3 substituents selected from R1, R2, R3, R4, or R5;
  • G is N or CRx;
  • Rx is H, halo, CN, R2, OR6, —(CH2)wOC(O)R2, C(O)OR2, C(O)NH2, C(O)NHR2, or C(O)N(R2)2;
  • A is selected from:
  • Figure US20100105693A1-20100429-C00003
  • or A is adamantyl or adamantylmethyl;
  • wherein:
  • bond r is a single or double bond;
  • when ring B is present, then bond r is fused with B;
  • each of X1, X3 and X4 is independently selected from CH2, CH2—CH2, O, S, SO2, NR, wherein R is R2 or R4;
  • X2 is CH;
  • each of W1, W3, and W4 is independently selected from a bond, —(CH2)i—, —(CH2)iNRiC(O)—, —(CH2)iC(O)NRi—, —(CH2)iNRiSO2—, —(CH2)iSO2NRi—, C(O), O, S, NH, or S(O)2;
  • Ri is H or R2;
  • W2 and X2 taken together are selected from CH, CH2—CH, —(CH2)iC(O)N—, or —(CH2)iSO2N—;
  • ring B, when present, is a 5-6 membered cycloaliphatic or 5-6 membered heterocyclic ring, in which the 5-6 membered cycloaliphatic or 5-6 membered heterocyclic ring are each optionally substituted with 1 to 3 substituents selected from R1, R2, R3, R4, or R5;
  • R1 is oxo or ((C1-C4)aliphatic)p-Y;
  • Y is halo, CN, NO2, CF3, OCF3, OH, SR6, S(O)R6, SO2R6, COOH, COOR6 or OR6; or
  • R2 is aliphatic, wherein each R2 optionally includes 1 to 2 substituents independently selected from R1, R4, or R5;
  • R3 is a cycloaliphatic, aryl, heterocyclic, or heteroaryl ring optionally including 1 to 3 substituents independently selected from R1, R2, R4, or R5;
  • R4 is OR5, OR6, S(O)R6, S(O)R5, SO2R6, SO2R5, SO2N(R6)2, SO2N(R5)2, SO2NR5R6, SO3R6, SO3R5, C(O)R5, C(O)OR5, C(O)R6, C(O)OR6, C(O)N(R6)2, C(O)N(R5)2, C(O)N(R5R6), C(O)N(OR6)R6, C(O)N(OR5)R6, C(O)N(OR6)R5, C(O)N(OR5)R5, C(NOR6)R6, C(NOR6)R5, C(NOR5)R6, C(NOR5)R5, NR5C(O)R5, NR6C(O)R6, NR6C(O)R5, NR6C(O)OR6, NR5C(O)OR6, NR6C(O)OR5, NR5C(O)OR5, NR6C(O)N(R6)2, NR6C(O)NR5R6, NR6C(O)N(R5)2, NR5C(O)N(R6)2, NR5C(O)NR5R6, NR5C(O)N(R5)2, NR6SO2R6, NR6SO2R5, NR5SO2R5, NR6SO2N(R6)2, NR6SO2NR5R6, NR6SO2N(R5)2, NR5SO2NR5R6, NR5SO2N(R5)2, N(OR6)R6, N(OR6)R5, N(OR5)R5, or N(OR5)R6;
  • R5 is a cycloaliphatic, aryl, heterocyclic, or heteroaryl ring, optionally including 1 to 3 R1 substituents;
  • R6 is H or aliphatic, wherein R6 optionally includes a R7 substituent;
  • R7 is a cycloaliphatic, aryl, heterocyclic, or heteroaryl ring, and each R7 optionally comprises up to 2 substituents independently chosen from H, (C1-C6)-straight or branched alkyl, (C2-C6) straight or branched alkenyl or alkynyl, 1,2-methylenedioxy, 1,2-ethylenedioxy, or (CH2)n—Z;
  • Each R8 is selected from R2, R3, or R4 or a protecting group.
  • Z is selected from halo, CN, NO2, CF3, OCF3, OH, S-aliphatic, S(O)-aliphatic, SO2-aliphatic, NH2, NH-aliphatic, N(aliphatic)2, COOH, C(O)O(-aliphatic), or O-aliphatic;
  • Each i is independently 1-3;
  • Each m is independently 1 or 2;
  • Each n is independently 0 or 1;
  • Each p is independently 0 or 1;
  • Each w is independently 0 or 1;
  • Each x is independently 1 or 2; and
  • with the proviso that the following compounds are not included:
    • 2-(4-bicyclo[2.2.1]hept-2-yl-1-piperazinyl)-pyrimidine;
    • 2-[4-(bicyclo[2.2.1]hept-5-en-2-ylmethyl)-1-piperazinyl]-pyrimidine;
    • 3-(1-bicyclo[2.2.1]hept-2-yl-4-piperidinyl)-2(3H)-benzoxazolone;
    • 1-[1-[(1R,2R,4S)-bicyclo[2.2.1]hept-2-ylmethyl]-4-piperidinyl]-1,3-dihydro-2H-indol-2-one;
    • 1-(1-bicyclo[2.2.1]hept-2-yl-4-piperidinyl)-3-ethylidene-1,3-dihydro-2H-indol-2-one;
    • 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-3,5-methano-2H-cyclopenta[b]furan-3 (3 aH)-yl)carbonyl]-piperazine;
    • 1-(1-bicyclo[2.2.1]hept-2-yl-4-piperidinyl)-3,4-dihydro-2(1H)-quinolinone;
    • 5-(1-bicyclo[2.2.1]hept-2-yl-4-piperidinyl)-3-bromo-N-(3-pyridinylmethyl)-pyrazolo[1,5-a]pyrimidin-7-amine;
    • 1-(1-bicyclo[2.2.1]hept-2-yl-4-piperidinyl)-3-ethyl-1,3-dihydro-2H-indol-2-one;
    • 1-(1-bicyclo[2.2.1]hept-2-yl-4-piperidinyl)-3,4-dihydro-2,2-dioxide-1H-2,1,3-benzothiadiazine;
    • 1-(1-bicyclo[2.2.1]hept-2-yl-4-piperidinyl)-1,3-dihydro-2H-Indol-2-one;
    • 1-[1-[(1R,2S,4S)-bicyclo[2.2.1]hept-2-ylmethyl]-4-piperidinyl]-1,3-dihydro-2H-indol-2-one;
    • [1-(1-bicyclo[2.2.1]hept-2-yl-4-piperidinyl)-3-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene]-cyanamide;
    • 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(bicyclo[2.2.1]hept-5-en-2-ylcarbonyl)-piperazine;
    • 5-(1-bicyclo[2.2.1]hept-2-yl-4-piperidinyl)-3-bromo-N-(3-pyridinylmethyl)-pyrazolo[1,5-a]pyrimidin-7-amine;
    • 1-[1-[(1R,2R,4S)-bicyclo[2.2.1]hept-2-ylmethyl]-4-piperidinyl]-1,3-dihydro-2H-indol-2-one;
    • 1-[1-[(1R,2S,4S)-bicyclo[2.2.1]hept-2-ylmethyl]-4-piperidinyl]-1,3-dihydro-2H-indol-2-one;
    • 3-(1-bicyclo[2.2.1]hept-2-yl-4-piperidinyl)-2(3H)-benzoxazolone;
    • 1-(1-bicyclo[2.2.1]hept-2-yl-4-piperidinyl)-1,3-dihydro-2H-Indol-2-one;
    • 1-(1-bicyclo[2.2.1]hept-2-yl-4-piperidinyl)-3-ethylidene-1,3-dihydro-2H-Indol-2-one;
    • 1-(1-bicyclo[2.2.1]hept-2-yl-4-piperidinyl)-3-ethyl-1,3-dihydro-2H-Indol-2-one;
    • 1-(1-bicyclo[2.2.1]hept-2-yl-4-piperidinyl)-3,4-dihydro-2,2-dioxide-1H-2,1,3-benzothiadiazine; and
    • 1-(1-bicyclo[2.2.1]hept-2-yl-4-piperidinyl)-3,4-dihydro-2(1H)-quinolinone.
  • According to another aspect, the present invention provides a compound having formula (II):
  • Figure US20100105693A1-20100429-C00004
  • Wherein ring AII is selected from:
  • Figure US20100105693A1-20100429-C00005
  • Each XX, YY, and Z5 is independently CR′ or N;
  • Each XX1 and YY1 is independently selected from a bond, CH2, CHR90, O, S, NH, NR′, C(O), S(O), or SO2 provided that both X1 and Y1 are not simultaneously a bond;
  • when XX1 and YY1 are each CHR90, then the two R90 together with the atoms to which they are attached may form a 5 to 8 membered cycloaliphatic or heterocyclic fused ring.
  • Each Z6 is independently —C(R′)2—, —C(R′)2—C(R′)2—, —C(R′)2-Q-, or Q, wherein Q is O, —N(R′)—, —S(O)—, —SO2—, or —C(O)—;
  • Each Z1, Z2, Z3, and Z4 is independently selected from CH2, CHR′, O, S, NH, NR′, C(O), S(O), SO2;
  • Each R′ is independently selected from (C1-C4)aliphatic)mm-Q1, S(O)iR60, S(O)8R50, SO2N(R60)2, SO2N(R50)2, SO2NR50R60, C(O)R50, C(O)OR50, C(O)R60, C(O)OR60, C(O)N(R60)2, C(O)N(R50)2, C(O)N(R50R60), C(O)N(OR60)R60, C(O)N(OR50)R60, C(O)N(OR60)R50, C(O)N(OR50)R50, C(NOR60)R60, C(NOR60)R50, C(NOR50)R60, C(NOR50)R50, R20, or R60, provided that when any of XX1, YY1, Z6, Z1, Z2, Z3, and Z4 are NR′, then R′ is S(O)iR60, S(O)iR50, SO2N(R60)2, SO2N(R50)2, SO2NR50R60, C(O)R50, C(O)OR50, C(O)R60, C(O)OR60, C(O)N(R60)2, C(O)N(R50)2, C(O)N(R50R60), C(O)N(OR60)R60, C(O)N(OR50)R60, C(O)N(OR60)R50, C(O)N(OR50)R50, C(NOR60)R60, C(NOR60)R50, C(NOR50)R60, or C(NOR50)R50;
  • Each R10 is independently oxo or ((C1-C4)aliphatic)mm-Q1;
  • Each Q1 is independently halo, CN, NO2, CF3, OCF3, OH, SR60, S(O)R60, SO2R60, COOH, COOR60 or OR60;
  • Each R20 is independently aliphatic optionally substituted with 1-3 substituents independently selected from R10, R40, or R50;
  • Each R30 is independently a cycloaliphatic, aryl, heterocyclic, or heteroaryl ring, wherein each of the cycloaliphatic, aryl, heterocyclic, or heteroaryl are optionally substituted with 1-3 substituents independently selected from R10, R20, R40; or R50;
  • Each R40 is independently OR50, OR60, OC(O)R60, OC(O)R50, OC(O)OR60, OC(O)OR50, OC(O)N(R60)2, OC(O)N(R50)2, OC(O)N(R60R50), S(O)iR60, S(O)iR50, SO2N(R60)2, SO2N(R50)2, SO2NR50R60, C(O)R50, C(O)OR50, C(O)R60, C(O)OR60, C(O)N(R60)2, C(O)N(R50)2, C(O)N(R50R60), C(O)N(OR60)R60, C(O)N(OR50)R60, C(O)N(OR60)R50, C(O)N(OR50)R50, C(NOR60)R60, C(NOR60)R50, C(NOR50)R60, C(NOR50)R50, NR50C(O)R50, NR60C(O)R60, NR60C(O)R50, NR60C(O)OR60, NR50C(O)OR60, NR60C(O)OR50, NR50C(O)OR50, NR60C(O)N(R60)2, NR60C(O)NR50R60, NR60C(O)N(R50)2, NR50C(O)N(R60)2, NR50C(O)NR50R60, NR50C(O)N(R50)2, NR60SO2R60, NR60SO2R50, NR50SO2R50, NR60SO2N(R60)2, NR60SO2NR50R60, NR60SO2N(R50)2, NR50SO2NR50R60; NR50SO2N(R50)2, N(OR60)R60, N(OR60)R50, N(OR50)R50, or N(OR50)R60;
  • Each R50 is independently a cycloaliphatic, aryl, heterocyclic, or heteroaryl ring, wherein each of the cycloaliphatic, aryl, heterocyclic, or heteroaryl are optionally substituted with 1 to 3 of R10;
  • Each R60 is independently H or aliphatic optionally substituted with R70;
  • Each R70 is independently a cycloaliphatic, aryl, heterocyclic, or heteroaryl ring, wherein each of the cycloaliphatic, aryl, heterocyclic, or heteroaryl are optionally substituted with 1 to 2 of (C1-C6)-straight or branched alkyl, (C2-C6) straight or branched alkenyl or alkynyl, 1,2-methylenedioxy, 1,2-ethylenedioxy, or (CH2)nn-Q2;
  • Each Q2 is independently selected from halo, CN, NO2, CF3, OCF3, OH, S-aliphatic, S(O)-aliphatic, SO2-aliphatic, COOH, C(O)O-aliphatic, or O-aliphatic;
  • bond r is a single or double bond;
  • Each R80 is independently an amino protecting group;
  • Each R90 is independently R2, R3, or R6;
  • Each ii is independently 0, 1, 2, or 3;
  • Each mm is independently 0 or 1;
  • Each nn is independently 0 or 1;
  • Each f is 0, 1 or 2; and
  • Each g is 0, 1 or 2,
  • with the proviso that the following compounds are not included:
    • 2-(4-bicyclo[2.2.1]hept-2-yl-1-piperazinyl)-pyrimidine;
    • 2-[4-(bicyclo[2.2.1]hept-5-en-2-ylmethyl)-1-piperazinyl]-pyrimidine;
    • 3-(1-bicyclo[2.2.1]hept-2-yl-4-piperidinyl)-2(3H)-benzoxazolone;
    • 1-[1-[(1R,2R,4S)-bicyclo[2.2.1]hept-2-ylmethyl]-4-piperidinyl]-1,3-dihydro-2H-indol-2-one;
    • 1-(1-bicyclo[2.2.1]hept-2-yl-4-piperidinyl)-3-ethylidene-1,3-dihydro-2H-indol-2-one;
    • 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-3,5-methano-2H-cyclopenta[b]furan-3(3 aH)-yl)carbonyl]-piperazine;
    • 1-(1-bicyclo[2.2.1]hept-2-yl-4-piperidinyl)-3,4-dihydro-2(1H)-quinolinone;
    • 5-(1-bicyclo[2.2.1]hept-2-yl-4-piperidinyl)-3-bromo-N-(3-pyridinylmethyl)-pyrazolo[1,5-a]pyrimidin-7-amine;
    • 1-(1-bicyclo[2.2.1]hept-2-yl-4-piperidinyl)-3-ethyl-1,3-dihydro-2H-indol-2-one;
    • 1-(1-bicyclo[2.2.1]hept-2-yl-4-piperidinyl)-3,4-dihydro-2,2-dioxide-1H-2,1,3-benzothiadiazine;
    • 1-(1-bicyclo[2.2.1]hept-2-yl-4-piperidinyl)-1,3-dihydro-2H-Indol-2-one;
    • 1-[1-[(1R,2S,4S)-bicyclo[2.2.1]hept-2-ylmethyl]-4-piperidinyl]-1,3-dihydro-2H-indol-2-one;
    • 1-(1-bicyclo[2.2.1]hept-2-yl-4-piperidinyl)-3-ethyl-1,3-dihydro-2H-benzimidazol-2-ylidene-cyanamide;
    • 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(bicyclo[2.2.1]hept-5-en-2-ylcarbonyl)-piperazine;
    • 5-(1-bicyclo[2.2.1]hept-2-yl-4-piperidinyl)-3-bromo-N-(3-pyridinylmethyl)-pyrazolo[1,5-a]pyrimidin-7-amine;
    • 1-[1-[(1R,2R,4S)-bicyclo[2.2.1]hept-2-ylmethyl]-4-piperidinyl]-1,3-dihydro-2H-indol-2-one;
    • 1-[1-[(1R,2S,4S)-bicyclo[2.2.1]hept-2-ylmethyl]-4-piperidinyl]-1,3-dihydro-2H-indol-2-one;
    • 3-(1-bicyclo[2.2.1]hept-2-yl-4-piperidinyl)-2(3H)-benzoxazolone;
    • 1-(1-bicyclo[2.2.1]hept-2-yl-4-piperidinyl)-1,3-dihydro-2H-Indol-2-one;
    • 1-(1-bicyclo[2.2.1]hept-2-yl-4-piperidinyl)-3-ethylidene-1,3-dihydro-2H-Indol-2-one;
    • 1-(1-bicyclo[2.2.1]hept-2-yl-4-piperidinyl)-3-ethyl-1,3-dihydro-2H-Indol-2-one;
    • 1-(1-bicyclo[2.2.1]hept-2-yl-4-piperidinyl)-3,4-dihydro-2,2-dioxide-1H-2,1,3-benzothiadiazine; and
    • 1-(1-bicyclo[2.2.1]hept-2-yl-4-piperidinyl)-3,4-dihydro-2(1H)-quinolinone.
  • According to another embodiment, the present invention provides compounds of formula (III):
  • Figure US20100105693A1-20100429-C00006
  • wherein:
  • r is 0-3;
  • M is N or CH;
  • E is a 3-6 membered unsaturated or aromatic, monocyclic, heterocyclic ring containing 1-3 ring nitrogen heteroatoms, or
  • E is
  • Figure US20100105693A1-20100429-C00007
  • wherein E is optionally substituted with up to four substituents independently selected from R1, R2, R3, R4, or R5;
  • D is N or CR″;
  • R″ is H, halo, CN, R2, OR6, —(CH2)wOC(O)R2, C(O)OR2, C(O)NH2, C(O)NHR2, or C(O)N(R2)2;
  • R′ is R2;
  • x is 1 or 2;
  • wherein p, Y, R1, R2, R3, R4 and R5 are as defined above in formula (I); provided that:
  • (i) when D is N, R′ is t-butyl, then E is not 5-cyano-4-[(2,4-difluorophenyl)methyl]amino-2-pyrimidinyl;
  • (ii) when D is N, R′ is t-butyl, then E is not 5-ethoxycarbonyl-2-pyrimidinyl or pyridine-2-yl-5-carboxylic acid;
  • (iii) when D is CH, R′ is methyl, then E is not 3-amino-2-pyridinyl;
  • (iv) when D is N, R′ is t-butyl, then E is not 5-carboxy-4-(1-methyethyl)-2-thiazolyl; or
  • (v) when D is N, R′ is ethyl, then E is not 4-chloro-1,2,5-thiadiazol-3-yl.
  • According to another embodiment, the present invention provides compounds of formula (IV):
  • Figure US20100105693A1-20100429-C00008
  • or a pharmaceutically acceptable salt thereof,
    wherein
  • AIV is adamantanyl, adamantanylmethyl, or
  • Figure US20100105693A1-20100429-C00009
  • Bond r is a single or double bond;
  • Each X1 is independently selected from CH2, CH2—CH2, or NR400,
  • Each W1 is independently selected from a bond, —(CH2)i—, —(CH2)iNRiC(O)—, —(CH2)iC(O)NRi—, —(CH2)iNRiSO2—, —(CH2)iSO2NRi—, C(O), O, S, NH, or S(O)2;
  • Ri is H or R2;
  • R2 is aliphatic, wherein each R2 optionally includes 1 to 2 substituents independently selected from R100, R4, or R5;
  • R4 is OR5, OR6, S(O)R6, S(O)R5, SO2R6, SO2R5, SO2N(R6)2, SO2N(R5)2, SO2NR5R6, SO3R6, SO3R5, C(O)R5, C(O)OR5, C(O)R6, C(O)OR6, C(O)N(R6)2, C(O)N(R5)2, C(O)N(R5R6), C(O)N(OR6)R6, C(O)N(OR5)R6, C(O)N(OR6)R5, C(O)N(OR5)R5, C(NOR6)R6, C(NOR6)R5, C(NOR5)R6, C(NOR5)R5, NR5C(O)R5, NR6C(O)R6, NR6C(O)R5, NR6C(O)OR6, NR5C(O)OR6, NR6C(O)OR5, NR5C(O)OR5, NR6C(O)N(R6)2, NR6C(O)NR5R6, NR6C(O)N(R5)2, NR5C(O)N(R6)2, NR5C(O)NR5R6, NR5C(O)N(R5)2, NR6SO2R6, NR6SO2R5, NR5SO2R5, NR6SO2N(R6)2, NR6SO2NR5R6, NR6SO2N(R5)2, NR5SO2NR5R6, NR5SO2N(R5)2, N(OR6)R6, N(OR6)R5, N(OR5)R5, or N(OR5)R6;
  • Each R5 is independently a cycloaliphatic, aryl, heterocyclic, or heteroaryl ring, each optionally including 1 to 3 R100 substituents;
  • Each R6 is independently H or aliphatic optionally substituted with R7;
  • Each R7 is independently a cycloaliphatic, aryl, heterocyclic, or heteroaryl ring, each optionally substituted with up to 2 substituents independently selected from H, (C1-C6)-straight or branched alkyl, (C2-C6) straight or branched alkenyl or alkynyl, 1,2-methylenedioxy, 1,2-ethylenedioxy, or (CH2)n—Z;
  • Each R8 is independently selected from R2, R3, or R4 or a protecting group.
  • Each Z is independently selected from halo, —CN, —NO2, —CF3, —OCF3, —OH, —S-aliphatic, —S(O)-aliphatic, —SO2-aliphatic, —COOH, —C(O)O(-aliphatic), or —O-aliphatic;
  • G is N or C(H);
  • V is
  • Figure US20100105693A1-20100429-C00010
  • in which the benzotriazole is optional substituted with 1-3 of R100, R2, R4, R5, or R6;
  • Each Z1 and Z3 is independently —N═, —C(H)═, or —C(R100)═;
  • Each Z2 is independently a carbon atom;
  • Each Z4 and Z6 is independently —N═, —C(H)═ or —C(R100)═;
  • Each Z5 is independently —N═, —C(H)═, or —C(R200)═,
  • provided
      • a) that at least one of Z1, Z3, and Z5 is —N═;
      • b) that no more than two of Z1, Z2, Z3, Z4, and Z5 are —N═;
      • c) that no more than three of Z1, Z3, Z4, Z5, and Z6 are other than —N═ or —C(H)═;
      • d) when Z4 or Z6 is —C(R100)═, that (i) one of Z1 and Z3 is —C(R100)═, (ii) Z5 is —C(R200)═, or (iii) both Z4 and Z6 are —C(R100)═;
  • Each R100 is independently is —((C1-C4)aliphatic)p-Y2;
  • Y2 is halo, —CN, —NO2, —CF3, —OCF3, —SR600, —S(O)R600, —SO2R600, —SO2NR600, —COOR600, —C(O)N(R600)2, or —OR600; or
  • Each R200 is independently R100 or phenyl optionally substituted with 1-3 halo, —CN, —NO2, —CF3, —OCF3, —OH;
  • Each R400 is independently OR5, OR6, S(O)R6, S(O)R5, SO2R6, SO2R5, SO2N(R6)2, SO2N(R5)2, SO2NR5R6, SO3R6, SO3R5, C(O)R5, C(O)OR5, C(O)R6, C(O)OR6, C(O)N(R6)2, C(O)N(R5)2, C(O)N(R5R6), C(O)N(OR6)R6, C(O)N(OR5)R6, C(O)N(OR6)R5, C(O)N(OR5)R5, C(NOR6)R6, C(NOR6)R5, C(NOR5)R6, and C(NOR5)R5;
  • Each R600 is independently H or aliphatic optionally substituted with 1-3 substituents selected from halo, —CN, —NO2, —CF3, —OCF3, or —OH;
  • Each x is independently 1 or 2;
  • Each i is 0, 1 2, or 3;
  • Each m is independently 1 or 2; and
  • Each p is independently 0 or 1;
  • Each w is independently 0 or 1;
  • further provided that
  • (1) when G is N and AIV is bicyclo[2.2.1]hept-5-en-2-yl-carbonyl, then V is not 2-(phenyl)-6-acetamidoethyl-amino-pyrimidin-4-yl or 2-(4-chlorophenyl)-6-acetamidoethyl-amino-pyrimidin-4-yl;
  • (2) the compound is not 2-(4-bicyclo[2.2.1]hept-2-yl-1-piperazinyl)-pyrimidine or 2-[4-(bicyclo[2.2.1]hept-5-en-2-ylmethyl)-1-piperazinyl]-pyrimidine; and
  • (3) when G is N and AIV is azabicyclo[3.2.1]octane-8-carboxylic acid t-butyl ester, then V is not 5-cyano-4-[(2,4-difluorophenyl)methyl]amino-2-pyrimidinyl, 5-ethoxycarbonyl-2-pyrimidinyl, or pyridine-2-yl-5-carboxylic acid.
    • III. Specific Embodiments Ring A, AII and AIV
  • Ring A is used interchangeably with Ring AII and Ring AIV. According to one embodiment, A is selected from:
  • Figure US20100105693A1-20100429-C00011
  • wherein W1 is as defined above.
  • According to another embodiment, A is (ia). Or, A is (ib). Or, A is (ic).
  • According to one embodiment, x is 1. Or, x is 2.
  • According to another embodiment, W1 is a bond or CH2.
  • According to another embodiment, A is selected from:
  • Figure US20100105693A1-20100429-C00012
  • wherein W2 is as defined above.
  • According to one embodiment, A is selected from (iia), (iib), or (iic). Or, A is (iia). Or, A is (iib). Or, A is (iic).
  • According to one embodiment, W2 is a bond or CH2.
  • According to one embodiment, A is selected from:
  • Figure US20100105693A1-20100429-C00013
  • wherein W3 is as defined above.
  • According to one embodiment, A is (iiia). Or, A is (iiib). Or, A is (iiic).
  • According to one embodiment, W3 is a bond or CH2.
  • According to another embodiment, A is selected from:
  • Figure US20100105693A1-20100429-C00014
  • wherein W4 is as defined above.
  • According to another embodiment, A is selected from:
  • Figure US20100105693A1-20100429-C00015
  • wherein W4 is as defined above.
  • According to one embodiment, A is (iva). According to another embodiment, A is (ivb).
  • According to one embodiment, W4 is a bond or CH2.
  • According to another embodiment, A is adamantyl or adamantylmethyl.
  • According to another embodiment, A is
  • Figure US20100105693A1-20100429-C00016
  • wherein r, M and R′ are defined above in formula III. In one aspect of this embodiment, r is 0. In another aspect of this embodiment, r is 1. In still another aspect of this embodiment, r is 2. M is CH. M is N. R′ is aliphatic. R′ is alkyl. R′ is methyl, ethyl, n-propyl, n-butyl, t-butyl, or isopropyl.
  • According to another embodiment, (i) when G is N and V is pyrimidin-2-yl, then A is not bicyclo[2.2.1]hept-2-yl or bicyclo[2.2.1]hept-5-en-2-yl; or (ii) when G is N and A is bicyclo[2.2.1]hept-5-en-2-yl-carbonyl, then V is not 2-(phenyl)-6-acetamidoethyl-amino-pyrimidin-4-yl or 2-(4-chlorophenyl)-6-acetamidoethyl-amino-pyrimidin-4-yl.
    • Ring V in Formulae I, II, and IV and Ring E in Formula III
  • According to a preferred embodiment, ring V is a six-membered aromatic ring containing 1-3 nitrogen ring atoms. According to one embodiment, ring V is a six-membered aromatic ring containing 1 nitrogen ring atom. According to another embodiment, ring V is a six-membered aromatic ring containing 2 nitrogen ring atoms. According to another embodiment, V is a 5-6 membered unsaturated, monocyclic, heterocyclic ring containing 1-4 ring heteroatoms selected from O, S, and N.
  • According to one embodiment, ring V or ring E is selected from optionally substituted:
  • Figure US20100105693A1-20100429-C00017
  • In one aspect of this embodiment, each of the c-ring systems (a) through (k) is optionally substituted with 1 to 3 substituents selected from R1, R2, R3, R4, or R5.
  • According to another embodiment, ring V or ring E is
  • Figure US20100105693A1-20100429-C00018
  • wherein ring E is optionally substituted with up to four substituents independently selected from R1, R2, R3, R4, or R5.
  • According to another embodiment, ring V or ring E is
  • Figure US20100105693A1-20100429-C00019
  • According to another embodiment, ring V or ring E is an optionally substituted pyridyl or pyrazinyl. Preferred substituents on ring V or ring E include halo, cyano, C1-C4 alkyl, or CF3. More preferably, ring V or ring E is 3-cyano-2-pyridyl or 5-cyano-2-pyridyl.
  • According to another embodiment, ring V or ring E is contains up to 3 R1 substituents, wherein each R1 is independently as defined above. Or, ring V or ring E contains 1 or 2 R1 substituents, wherein each R1 is independently as defined herein. Ring V or ring E contains 1 to 3 of halo, cyano, C1-C4 alkyl, or CF3.
    • Substituents R1, R2, R3, R4, R5, R6, and R7
  • According to another preferred embodiment, R1 is R6, wherein R6 is straight chain or branched (C1-C6)alkyl or (C2-C6 alkenyl) or alkynyl, optionally substituted with R7.
  • According to another preferred embodiment, R1 is (CH2)m—Y, wherein m is 0, 1, or 2, and Y is halo, CN, NO2, CF3, OCF3, OH, SR6,S(O)R6, SO2R6, COOH, COOR6 or OR6.
  • According to another preferred embodiment, R1 is selected from halo, CF3, CN, NH2, NH(C1-C4 alkyl), NHC(O)CH3, OH, O(C1-C4 alkyl), OPh, O-benzyl, S—(C1-C4 alkyl), C1-C4 aliphatic, NO2, CN, methylenedioxy, ethylenedixoy, SO2NH(C1-C4 alkyl), or SO2N(C1-C4 alkyl)2.
  • According to another more preferred embodiment, R1 is selected from methyl, n-propyl, i-propyl, t-butyl. Or, R1 is selected from CN, halo, NO2, CF3, OCF3, or OH, preferably CN. Or, R1 is selected from NH(CH3), NHC(O)CH3, OCH3, OPh, O-benzyl, S—(C2H5), S—CH3-methylenedioxy, SO2NH(n-propyl), or SO2N(n-propyl)2. Or, R1 is selected from NHC(O)CH3, OCH3, OPh, O-benzyl, S—(C2H5), S—CH3-methylenedioxy, SO2NH(n-propyl), or SO2N(n-propyl)2.
  • According to a preferred embodiment, R2 is a straight chain or branched (C1-C6)alkyl or (C2-C6) alkenyl or alkynyl, optionally substituted with R1, R4, or R5. More preferably, R2 is a straight chain or branched (C1-C4)alkyl or (C2-C4) alkenyl or alkynyl, optionally substituted with R1, R4, or R5.
  • According to a preferred embodiment, R3 is optionally substituted phenyl, napthyl, C5-C10 heteroaryl or C3-C7 heterocyclyl. More preferably, R3 is an optionally substituted phenyl, C5-C6 heteroaryl, or C3-C6 heterocyclyl.
  • According to a preferred embodiment, R4 is selected from OR5 or OR6.
  • According to a preferred embodiment, R5 is C5-C6 cycloalkyl, C6 or C10 aryl, C5-C10 heteroaryl or C3-C7 heterocyclyl, optionally substituted with up to 2 R1. More preferably, R5 is an optionally substituted cyclohexyl, phenyl, C5-C6 heteroaryl, or C3-C6 heterocyclyl.
  • According to a preferred embodiment, R6 is H.
  • According to another preferred embodiment, R6 is a straight chain or branched (C1-C6)alkyl or (C2-C6 alkenyl) or alkynyl, optionally substituted with R7.
  • According to another preferred embodiment, R6 is a straight chain or branched (C1-C6)alkyl or (C2-C6 alkenyl) or alkynyl.
  • According to a preferred embodiment, R7 is C5-C6 cycloalkyl, phenyl, naphthyl, C5-C10 heteroaryl or C3-C7 heterocyclyl, optionally substituted with straight chain or branched (C1-C6)alkyl or (C2-C6 alkenyl) or alkynyl. Or, R7 is C5-C6 cycloalkyl, phenyl, naphthyl, C5-C10 heteroaryl or C3-C7 heterocyclyl, optionally substituted with 1-2-methylenedioxy, 1,2-ethylenedioxy, or (CH2)n—Z. More preferably, R7 is an optionally substituted cyclohexyl, phenyl, C5-C6 heteroaryl, or C3-C6 heterocyclyl.
    • Basic Nitrogen Atoms
  • In some embodiments, the compounds of formulae I and II do not include any additional basic nitrogen atoms other than those contained within the V ring, E ring, A ring, or the piperazine/piperidine ring. For example, the substituents, if any, on the V ring, E ring, A ring or the piperazine/piperidine ring do not include any basic nitrogen atoms, wherein a basic nitrogen atom is defined as any nitrogen whose conjugate acid pka is greater than 7.1. For instance, the nitrogen atom at the 4 position relative to V is a basic nitrogen atom. In other embodiments, A and substituents attached to A do not include any basic nitrogen atoms, but V along with substituents attached to V may include one or more basic nitrogen atoms. Alternatively, ring A does not include any basic nitrogen atoms that form ring A, such as the nitrogen in piperidine, but V and substituents attached to V and A may include one or more basic nitrogen atoms.
    • Specific Embodiments
  • Specific embodiments of compounds useful for modulating muscarininc receptors includes all combinations of the generic descriptions, specific aspects, and embodiments described above.
  • According to a preferred embodiment, the specific compounds of formulae (I, II, III, or IV) are selected from Table 1 below:
  • TABLE 1
    1 1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-(3-nitro-2-pyridyl)-piperazine
    2 2-[4-(2-adamantyl)piperazin-1-yl]nicotinonitrile
    3 2-(4-norbornan-2-ylpiperazin-1-yl)-6-(trifluoromethyl)nicotinonitrile
    4 2-[1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-piperidyl]-4,6-dimethoxy-pyrimidine
    5 1-(3-nitro-2-pyridyl)-4-norbornan-2-yl-piperazine
    6 2-[4-(5-bicyclo[2.2.1]hept-2-enylmethyl)piperazin-1-yl]nicotinamide
    7 1-(3-chloro-2-pyridyl)-4-norbornan-2-yl-piperazine
    8 2-[4-(norbornan-2-ylmethyl)piperazin-1-yl]-6-(trifluoromethyl)nicotinonitrile
    9 1-[1-(3-bicyclo[3.2.1]octyl)-4-piperidyl]-1H-benzotriazole
    10 2-(4-norbornan-2-ylpiperazin-1-yl)nicotinamide
    11 3-[4-(4-cyano-6-phenyl-pyridazin-3-yl)piperazin-1-yl]-8-azabicyclo[3.2.1]octane-8-
    carboxylic acid ethyl ester
    12 3-[4-(3-cyano-2-pyridyl)piperazin-1-yl]-8-azabicyclo[3.2.1]octane-8-carboxylic acid
    ethyl ester
    13 6-[4-(5-bicyclo[2.2.1]hept-2-enylmethyl)piperazin-1-yl]nicotinonitrile
    14 6-[4-(norbornan-2-ylmethyl)piperazin-1-yl]nicotinamide
    15 1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-(6-methyl-2-pyridyl)-piperazine
    16 3-[4-(5-bicyclo[2.2.1]hept-2-enylmethyl)piperazin-1-yl]-2,5-dimethyl-pyrazine
    17 2-[4-(5-bicyclo[2.2.1]hept-2-enylmethyl)piperazin-1-yl]-3-methyl-pyrazine
    18 1-norbornan-2-yl-4-(4-pyridyl)piperazine
    19 6-(4-norbornan-2-ylpiperazin-1-yl)nicotinonitrile
    20 2-[4-(5-bicyclo[2.2.1]hept-2-enylmethyl)piperazin-1-yl]-3-methyl-pyridine
    21 1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-(6-chloro-2-pyridyl)-piperazine
    22 5-ethyl-2-[4-(norbornan-2-ylmethyl)piperazin-1-yl]-pyrimidine
    23 3-[4-(4-bicyclo[3.2.1]octylmethyl)piperazin-1-yl]pyrazine-2-carbonitrile
    24 3-[4-[3-cyano-6-(trifluoromethyl)-2-pyridyl]piperazin-1-yl]-8-
    azabicyclo[3.2.1]octane-8-carboxylic acid ethyl ester
    25 3-[4-(4-pyridyl)piperazin-1-yl]-8-azabicyclo[3.2.1]octane-8-carboxylic acid ethyl
    ester
    26 1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-(3,5-dichloro-4-pyridyl)-piperazine
    27 2-[4-(3-bicyclo[3.2.1]octyl)piperazin-1-yl]nicotinonitrile
    28 3-[4-[5-(trifluoromethyl)-2-pyridyl]piperazin-1-yl]-8-azabicyclo[3.2.1]octane-8-
    carboxylic acid ethyl ester
    29 3-[4-(1H-benzotriazol-1-yl)-1-piperidyl]-8-azabicyclo[3.2.1]octane-8-carboxylic acid
    ethyl ester
    30 3-[4-(3-fluoro-2-pyridyl)piperazin-1-yl]-8-azabicyclo[3.2.1]octane-8-carboxylic acid
    ethyl ester
    31 6-methyl-2-(4-norbornan-2-ylpiperazin-1-yl)-nicotinonitrile
    32 2-(4-norbornan-2-ylpiperazin-1-yl)nicotinonitrile
    33 3-[4-(3-cyano-5-phenyl-2-pyridyl)piperazin-1-yl]-8-azabicyclo[3.2.1]octane-8-
    carboxylic acid ethyl ester
    34 6-[4-(5-bicyclo[2.2.1]hept-2-enylmethyl)piperazin-1-yl]nicotinonitrile
    35 1-(3-bicyclo[3.2.1]octyl)-4-(4-pyridyl)piperazine
    36 3-[4-(5-carbamoyl-2-pyridyl)piperazin-1-yl]-8-azabicyclo[3.2.1]octane-8-carboxylic
    acid ethyl ester
    37 1-[1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-piperidyl]-1H-benzotriazole
    38 3-[[4-(3-cyanopyrazin-2-yl)piperazin-1-yl]methyl]-8-azabicyclo[3.2.1]octane-8-
    carboxylic acid ethyl ester
    39 2-[4-(5-bicyclo[2.2.1]hept-2-enylmethyl)piperazin-1-yl]pyrazine
    40 2,5-dimethyl-3-(4-norbornan-2-ylpiperazin-1-yl)-pyrazine
    41 1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-(4-pyridyl)piperazine
    42 2-[4-(5-bicyclo[2.2.1]hept-2-enylmethyl)piperazin-1-yl]nicotinonitrile
    43 3-(4-norbornan-2-ylpiperazin-1-yl)pyrazine-2-carbonitrile
    44 2-(4-norbornan-2-ylpiperazin-1-yl)pyrazine
    45 3-[4-(3-cyanopyrazin-2-yl)piperazin-1-yl]-8-azabicyclo[3.2.1]octane-8-carboxylic
    acid ethyl ester
    46 2-[4-(norbornan-2-ylmethyl)piperazin-1-yl]-5-phenyl-nicotinonitrile
    47 1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-[5-(trifluoromethyl)-2-pyridyl]-piperazine
    48 1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-(2-pyridyl)piperazine
    49 3-[4-(3-sulfamoyl-4-pyridyl)piperazin-1-yl]-8-azabicyclo[3.2.1]octane-8-carboxylic
    acid ethyl ester
    50 1-(1-norbornan-2-yl-4-piperidyl)-1H-benzotriazole
    51 3-[4-(5-acetyl-2-pyridyl)piperazin-1-yl]-8-azabicyclo[3.2.1]octane-8-carboxylic acid
    ethyl ester
    52 1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-(3-chloro-2-pyridyl)-piperazine
    53 2-[4-(5-bicyclo[2.2.1]hept-2-enylmethyl)piperazin-1-yl]-6-
    (trifluoromethyl)nicotinonitrile
    54 2-[1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-piperidyl]nicotinonitrile
    55 4-[4-(norbornan-2-ylmethyl)piperazin-1-yl]pyridine-3-sulfonamide
    56 3-[4-(4-cyano-2-pyridyl)piperazin-1-yl]-8-azabicyclo[3.2.1]octane-8-carboxylic acid
    ethyl ester
    57 3-[4-(4,6-dimethoxypyrimidin-2-yl)-1-piperidyl]-8-azabicyclo[3.2.1]octane-8-
    carboxylic acid ethyl ester
    58 3-[4-[6-chloro-3-cyano-4-(trifluoromethyl)-2-pyridyl]piperazin-1-yl]-8-
    azabicyclo[3.2.1]octane-8-carboxylic acid ethyl ester
    59 3-[4-(norbornan-2-ylmethyl)piperazin-1-yl]-6-phenyl-pyridazine-4-carbonitrile
    60 1-(3-methyl-2-pyridyl)-4-norbornan-2-yl-piperazine
    61 1-(2-bicyclo[3.2.1]octyl)-4-(4-pyridyl)piperazine
    62 2-[4-(5-bicyclo[2.2.1]hept-2-enylmethyl)piperazin-1-yl]-6-methyl-nicotinonitrile
    63 2-methyl-3-(4-norbornan-2-ylpiperazin-1-yl)-pyrazine
    64 2-[4-(4-bicyclo[3.2.1]octylmethyl)piperazin-1-yl]nicotinonitrile
    65 1-norbornan-2-yl-4-(2-pyridyl)piperazine
    66 3-[4-(5-cyano-2-pyridyl)piperazin-1-yl]-8-azabicyclo[3.2.1]octane-8-carboxylic acid
    ethyl ester
    67 3-[4-(5-ethylpyrimidin-2-yl)piperazin-1-yl]-8-azabicyclo[3.2.1]octane-8-carboxylic
    acid ethyl ester
    68 3-[[4-(3-cyano-2-pyridyl)piperazin-1-yl]methyl]-8-azabicyclo[3.2.1]octane-8-
    carboxylic acid ethyl ester
    69 1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-[3-(trifluoromethyl)-2-pyridyl]-piperazine
    70 3-[4-(5-bicyclo[2.2.1]hept-2-enylmethyl)piperazin-1-yl]pyrazine-2-carbonitrile
    71 2-(4-norbornan-2-ylpiperazin-1-yl)pyrimidine
    72 4,6-dimethyl-2-(4-norbornan-2-ylpiperazin-1-yl)-pyrimidine
    73 6-methyl-2-[4-(norbornan-2-ylmethyl)piperazin-1-yl]-5-phenyl-nicotinonitrile
    74 1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-[3-chloro-5-(trifluoromethyl)-2-pyridyl]-
    piperazine
    75 1-(2-adamantyl)-4-(4-pyridyl)piperazine
    76 2-[4-(5-bicyclo[2.2.1]hept-2-enylmethyl)piperazin-1-yl]pyrimidine
    77 1-(6-methyl-2-pyridyl)-4-norbornan-2-yl-piperazine
    78 3-[4-(3-cyano-4,6-dimethyl-2-pyridyl)piperazin-1-yl]-8-azabicyclo[3.2.1]octane-8-
    carboxylic acid ethyl ester
    • Iv. Synthetic Schemes
  • The compounds of formulae (I, II, III, and IV) may be readily synthesized using methods known in the art. An exemplary synthetic route to produce compounds of formulae (I, II, III, and IV) is provided below in Scheme 1.
  • Figure US20100105693A1-20100429-C00020
  • Referring to Scheme 1, the reaction of piperazine with a ring V compound bearing a suitable leaving group X, optionally in the presence of a coupling catalyst, produces an intermediate that upon reaction with A-Y, wherein Y is a suitable functionality, in the presence of a suitable reducing agent using, produces compounds of formula (I).
  • Examples of X include halogen, tosylate, mesylate and triflate. Examples of a suitable functionality Y include an aldehyde or a ketone. An example of a suitable reducing agent includes sodium triacetoxyborohydride. An non-limiting example of a coupling catalyst is acetato(2′-di-t-butylphosphino-1,1′-biphenyl-2-yl)palladium (II).
  • The synthetic route depicted above is generic and can be readily adapted for other embodiments of compound formulae (I, II, III, and IV). It will also be recognized that variations of Scheme I, for example introducing Ring A before Ring V (or Ring E) and conducting each attachment with the same or different chemistry for each step, also constitute suitable methods for the preparation of compounds of Formulae (I, II, III, and IV).
    • V. Formulations, Administrations, and Uses
  • The present invention includes within its scope pharmaceutically acceptable prodrugs of the compounds of the present invention. A “pharmaceutically acceptable prodrug” means any pharmaceutically acceptable salt, ester, salt of an ester, or other derivative of a compound of the present invention which, upon administration to a recipient, is capable of providing (directly or indirectly) a compound of this invention or an active metabolite or residue thereof. Preferred prodrugs are those that increase the bioavailability of the compounds of this invention when such compounds are administered to a mammal or which enhance delivery of the parent compound to a biological compartment relative to the parent species.
  • The term “pharmaceutically acceptable carrier, adjuvant, or vehicle” refers to a non-toxic carrier, adjuvant, or vehicle that does not destroy the pharmacological activity of the compound with which it is formulated. Pharmaceutically acceptable carriers, adjuvants or vehicles that may be used in the compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.
  • Pharmaceutically acceptable salts of the compounds of this invention include those derived from pharmaceutically acceptable inorganic and organic acids and bases. Examples of suitable acid salts include acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptanoate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, salicylate, succinate, sulfate, tartrate, thiocyanate, tosylate and undecanoate. Other acids, such as oxalic, while not in themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts.
  • Salts derived from appropriate bases include alkali metal (e.g., sodium and potassium), alkaline earth metal (e.g., magnesium), ammonium and N+(C1-4 alkyl)4 salts. This invention also envisions the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. Water or oil-soluble or dispersible products may be obtained by such quaternization.
  • The compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. The term “parenteral” as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. Preferably, the compositions are administered orally, intraperitoneally or intravenously. Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • For this purpose, any bland fixed oil may be employed including synthetic mono- or di-glycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents that are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions. Other commonly used surfactants, such as Tweens, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.
  • The pharmaceutically acceptable compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions. In the case of tablets for oral use, carriers commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried cornstarch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.
  • Alternatively, the pharmaceutically acceptable compositions of this invention may be administered in the form of suppositories for rectal administration. These can be prepared by mixing the agent with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug. Such materials include cocoa butter, beeswax and polyethylene glycols.
  • The pharmaceutically acceptable compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.
  • Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-transdermal patches may also be used.
  • For topical applications, the pharmaceutically acceptable compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers. Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. Alternatively, the pharmaceutically acceptable compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
  • For ophthalmic use, the pharmaceutically acceptable compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with or without a preservative such as benzylalkonium chloride. Alternatively, for ophthalmic uses, the pharmaceutically acceptable compositions may be formulated in an ointment such as petrolatum.
  • The pharmaceutically acceptable compositions of this invention may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.
  • Most preferably, the pharmaceutically acceptable compositions of this invention are formulated for oral administration.
  • The amount of the compounds of the present invention that may be combined with the carrier materials to produce a composition in a single dosage form will vary depending upon the host treated, the particular mode of administration. Preferably, the compositions should be formulated so that a dosage of between 0.01-100 mg/kg body weight/day of the modulator can be administered to a patient receiving these compositions.
  • It should also be understood that a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated. The amount of a compound of the present invention in the composition will also depend upon the particular compound in the composition.
  • Depending upon the particular condition, or disease, to be treated or prevented, additional therapeutic agents, which are normally administered to treat or prevent that condition, may also be present in the compositions of this invention. As used herein, additional therapeutic agents that are normally administered to treat or prevent a particular disease, or condition, are known as “appropriate for the disease, or condition, being treated.”
  • According to a preferred embodiment, the compounds of formulae (I, II, III, and IV) are selective modulators of M1, M2 and M4. More preferably, the compounds of formulae (I, II, III, and IV) are selective modulators of M1 and/or M4. Yet more preferably, the compounds of formulae (I, II, III, and IV) are selective modulators of one of M1. Or, preferably, the compounds of formulae (I, II, III, and IV) are selective modulators of M4.
  • Applicants believe that the ability of the compounds of the present invention to modulate the activity of muscarinic receptors is derived from the affinity of these compounds to the muscarinic receptors. Such affinity, applicants believe, activates a muscarinic receptor (i.e, an agonist) or inhibits the activity of a muscarinic receptor.
  • According to a preferred embodiment, the compounds of formula (I) are selective activators of M1, M2 and M4. More preferably, these compounds are selective activators of M1 and/or M4. Yet more preferably, the compounds of formula (I) are selective activators of M1. Or, preferably, the compounds of formula (I) are selective activators of M4.
  • According to another embodiment, the compounds of formula (II) are selective inhibitors of one or more of M1, M2, or M4. Preferably, the compounds of formula (II) are selective inhibitors of M1. Or, the compounds of formula (II) are selective inhibitors of M4.
  • According to another embodiment, the compounds of formula (III) are selective inhibitors of one or more of M1, M2, or M4. Preferably, the compounds of formula (III) are selective inhibitors of M1. Or, the compounds of formula (III) are selective inhibitors of M4.
  • According to another embodiment, the compounds of formula (IV) are selective inhibitors of one or more of M1, M2, or M4. Preferably, the compounds of formula (IV) are selective inhibitors of M1. Or, the compounds of formula (IV) are selective inhibitors of M4.
  • The term “selective” as used herein means a measurably greater ability to modulate one muscarinic receptor subtype when compared to the other muscarinic receptor subtypes. E.g., the term “selective M4 agonist” means a compound that has a measurably greater ability to act as an M4 agonist when compared to that compound's agonist activity with the other muscarinic receptor subtype(s).
  • According to an alternative embodiment, the present invention provides a method of treating a muscarinic receptor mediated disease in a mammal, comprising the step of administering to said mammal a composition comprising a compound of formula (I), or a preferred embodiment thereof as set forth above.
  • According to a preferred embodiment, the present invention provides a method of treating a disease mediated by a muscarinic receptor comprising the step of administering to said mammal a composition comprising a compound of formula (I), or a preferred embodiment thereof as set forth above. Preferably, said disease is mediated by M1. Or, said disease is mediated by M4.
  • According to a preferred embodiment, the present invention provides a method of treating or reducing the severity of a disease in a patient, wherein said disease is selected from CNS derived pathologies including cognitive disorders, Attention Deficit Hyperactivity Disorder (ADHD), obesity, Alzheimer's disease, various dementias such as vascular dementia, psychosis including schizophrenia, mania, bipolar disorders, pain conditions including acute and chronic syndromes, Huntington's Chorea, Friederich's ataxia, Gilles de la Tourette's Syndrome, Downs Syndrome, Pick disease, clinical depression, sudden infant death syndrome, Parkinson's disease, peripheral disorders such as reduction of intra ocular pressure in Glaucoma and treatment of dry eyes and dry mouth including Sjögren's Syndrome, wherein said method comprises the step of contacting said patient with a compound according to the present invention.
  • According to an alternative embodiment, the present invention provides a method of treating or reducing the severity of a disease in a patient, wherein said disease is selected from pain, psychosis (including schizophrenia, hallucinations, and delusions), Alzheimer's disease, Parkinson's disease, glaucoma, bradhycardia, gastric acid secretion, asthma, or GI disturbances.
  • According to a preferred embodiment, the present invention is useful for treating or reducing the severity of psychosis, Alzheimer's disease, pain, or Parkinson's disease.
  • In order that the invention described herein may be more fully understood, the following examples are set forth. It should be understood that these examples are for illustrative purposes only and are not to be construed as limiting this invention in any manner.
  • All references cited above are incorporated herein by reference.
    • EXAMPLES Example 1 Synthesis of 2-(4-Bicyclo[2.2.1]hept-2-yl-piperazin-1-yl)-6-trifluoromethyl-nicotinamide
  • Figure US20100105693A1-20100429-C00021
  • 449 mg (2.00 mmol, 1.0 eq) 2-Chloro-6-trifluoromethyl nicotinamide, 344 mg (4.00 mmol, 2.0 eq) piperazine and 2.0 mL anhydrous acetonitrile (ACN) were combined in a microwave vial and microwaved at 100° C. for 2 minutes. The reaction was diluted with 2.0 mL methanol and centrifuged (4,000 rpm, RT, 8 mins). The supernatant was filtered and purified by reverse-phase HPLC (1-25% CH3CN in 0.085% TFA (aq), 50 mL/min, 2×2.0 mL injected). The appropriate fractions were concentrated under reduced pressure. The resulting solids were dissolved in 5.0 mL 1.0 N sodium hydroxide and extracted with ethyl acetate (3×20 mL). The organic layers were combined, washed with brine, dried (Na2SO4) and concentrated under reduced pressure.
  • Yield=281 mg (51%) as off-white needles (isolated as the free base); Purity=99+%; 1H-NMR (400 MHz, DMSO-d6) δ 8.00 (br s, 1H), 7.83 (d, J=7.5 Hz, 1H), 7.69 (br s, 1H), 7.2 (d, J=7.6 Hz, 1H), 3.35 (br m, 4H), 2.79 (br m, 4H), 2.38 (br s, 1H); LC/MS retention time (10-99% CH3CN/0.085% TFA gradient over 5 min): 1.15 min; Theoretical (M+H)+ m/z for C11H13F3N4O=275.1; Found 275.0.
  • 55 mg (0.20 mmol, 1.0 eq) of 2-piperazin-1-yl-6-trifluoromethyl-nicotinamide was suspended in 5.0 mL anhydrous 1,2-dichloroethane and treated with 1.0 eq (22 mg) norcamphor. 2.0 eq (24 mg) glacial acetic acid was then added, followed by 2.8 eq (119 mg) sodium triacetoxyborohydride. The reaction vial was flushed with nitrogen and stirred at room temperature for 36 hours. The reaction mixture was concentrated under reduced pressure and the resulting residue dissolved in 2.0 mL DMSO:methanol (1:1). The solution was filtered and purified by reverse-phase HPLC (2-99% CH3CN in 0.085% TFA (aq), 50 mL/min, 2.0 mL injected). Yield=34 mg (35%) (isolated as the mono-TFA salt); Purity=99%; 1H-NMR (400 MHz, DMSO-d6) δ 9.32 (br s, 1H), 8.13 (s, 1H), 7.98 (d, J=7.5 Hz, 1H), 7.82 (s, 1H), 7.41 (d, J=7.6 Hz, 1H), 4.00 (m, 2H), 3.58 (br m, 3H), 3.41 (br m, 2H), 3.15 (br m, 2H), 2.62 (br s, 1H), 2.33 (br s, 1H), 2.02 (m, 1H), 1.59 (br m, 3H), 1.42 (m, 3H), 1.22 (m, 1H); LC/MS retention time (10-99% CH3CN/0.085% TFA gradient over 5 min): 1.91 min; Theoretical (M+H)+ m/z for C18H23F3N4O=369.2; Found 369.0.
    • Example 2 Synthesis of 1-Bicyclo[2.2.1]hept-5-en-2-ylmethyl-4-(2-methoxy-5-trifluoromethyl-pyridin-3-yl)-piperazine
  • Figure US20100105693A1-20100429-C00022
  • 2.5 mg (0.0050 mmol, 0.010 eq) Acetato(2′-di-t-butylphosphino-1,1′-biphenyl-2-yl)palladium (II) (A), 67 mg (0.70 mmol, 1.4 eq) NaOt-Bu and 1.0 mL anhydrous toluene were combined in a microwave vial. 106 mg (0.50 mmol, 1.0 eq) 3-Chloro-2-methoxy-5-trifluoromethylpyridine was added, followed by 129 mg (1.5 mmol, 3.0 eq) piperazine. The vial was flushed with nitrogen prior to being microwaved at 140° C. for 30 minutes. The reaction mixture was diluted with 1.0 mL DMSO:methanol (1:1), filtered and purified by reverse-phase HPLC (2-99% CH3CN in 0.085% TFA (aq), 50 mL/min, 2.0 mL injected). Yield=85 mg (45%)-(isolated as the mono-TFA salt); Purity=99%; 1H-NMR (400 MHz, DMSO-d6) δ 8.99 (br s, 2H), 8.24 (d, J=2.0 Hz, 1H), 7.51 (d, J=2.1 Hz, 1H), 4.02 (s, 3H), 3.32 (br m, 8H); LC/MS retention time (10-99% CH3CN/0.085% TFA gradient over 5 min): 1.73 min; Theoretical (M+H)+ m/z for C11H14F3N3O=262.1; Found 262.0.
  • 75 mg (0.20 mmol, 1.0 eq) of 1-(2-methoxy-5-trifluoromethyl-pyridin-3-yl)-piperazine (as the mono-TFA salt) was suspended in 1.0 mL anhydrous 1,2-dichloroethane and treated with 1.0 eq (20 mg) triethylamine. 1.0 eq (24 mg) 5-Norbornene-2-carboxaldehyde was added, followed by 1.4 eq (59 mg) sodium triacetoxyborohydride. The reaction was stirred at room temperature for 5 minutes, then quenched with 1.0 mL DMSO:methanol (1:1). The reaction mixture was filtered and purified by reverse-phase HPLC (2-99% CH3CN in 0.085% TFA (aq), 50 mL/min, 2.0 mL injected). Yield=23 mg (24%) (isolated as the mono-TFA salt); Purity=99%; 1H-NMR (400 MHz, DMSO-d6) δ 10.08 (br s, 1H), 8.25 (d, J=1.9 Hz, 1H), 7.50 (d, J=2.2 Hz, 1H), 6.28 (m, 0.8H), 6.18 (m, 0.4H), 6.07 (m, 0.8H), 4.02 (s, 3H), 3.71 (br m, 4H), 2.81-3.26 (m, 8H), 2.54 (m, 1H), 2.03 (m, 0.8H), 1.80 (m, 0.2H), 1.30-1.41 (m, 2.5H), 0.71 (m, 0.8H); LC/MS retention time (10-99% CH3CN/0.085% TFA gradient over 5 min): 2.30 min; Theoretical (M+H)+ m/z for C19H24F3N3O=368.2; Found 368.2.
    • Example 3 Synthesis of 4-Bicyclo[2.2.1]hept-5-en-2-ylmethyl-3,4,5,6-tetrahydro-2H-[1,2′]bipyrazinyl-3′-carbonitrile
  • Figure US20100105693A1-20100429-C00023
  • 70 mg (0.50 mmol, 1.0 eq) 3-Chloropyrazine-2-carbonitrile and 86 mg (1.0 mmol, 2.0 eq) piperazine were added to 1.0 mL anhydrous acetonitrile and stirred at room temperature for 5 minutes. The reaction was diluted with 1.0 mL methanol, filtered and purified by reverse-phase HPLC (1-25% CH3CN in 0.085% TFA (aq), 50 mL/min, 2.0 mL injected). Yield=63 mg (42%) (isolated as the mono-TFA salt); Purity=99%; 1H-NMR (400 MHz, DMSO-d6) δ 9.15 (br s, 2H), 8.56 (d, J=2.3 Hz, 1H), 8.27 (d, J=2.3 Hz, 1H), 3.94 (br m, 4H), 3.31 (br m, 4H); LC/MS retention time (10-99% CH3CN/0.085% TFA gradient over 5 min): 0.41 min; Theoretical (M+H)+ m/z for C9H11N5=190.1; Found 190.1.
  • 61 mg (0.20 mmol, 1.0 eq) of 3,4,5,6-Tetrahydro-2H-[1,2′]bipyrazinyl-3′-carbonitrile (as the mono-TFA salt) was suspended in 1.0 mL anhydrous 1,2-dichloroethane and treated with 1.0 eq (20 mg) triethylamine. 1.0 eq (24 mg) 5-Norbornene-2-carboxaldehyde was added, followed by 1.4 eq (59 mg) sodium triacetoxyborohydride. The reaction was stirred at room temperature for 5 minutes, then quenched with 1.0 mL DMSO:methanol (1:1). The reaction mixture was filtered and purified by reverse-phase HPLC (2-99% CH3CN in 0.085% TFA (aq), 50 mL/min, 2.0 mL injected). Yield=40 mg (49%) (isolated as the mono-TFA salt); Purity=99+%; 1H-NMR (400 MHz, DMSO-d6) δ 10.20 (br s, 1H), 8.57 (d, J=2.3 Hz, 1H), 8.29 (d, J=2.2 Hz, 1H), 6.28 (m, 0.8H), 6.18 (m, 0.4H), 6.05 (m, 0.8H), 4.47 (m, 2H), 3.55 and 3.71 (2 br m, 4H), 3.31 (m, 1H), 2.86-3.01 (br m, 4H), 2.54 (m, 1H), 2.02 (m, 0.8H), 1.80 (m, 0.2H), 1.30-1.41 (m, 3H), 0.68 (m, 0.8H); LC/MS retention time (10-99% CH3CN/0.085% TFA gradient over 5 min): 1.77 min; Theoretical (M+H)+ m/z for C17H21N5=296.2; Found 296.2.
    • Example 4
  • Additional compounds listed in Table 2 were produced via known methodologies and synthetic procedures and those described herein.
  • TABLE 2
    LCMS LCMS
    No. Name Plus RT
    1 1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-(3-nitro-2-pyridyl)- 315 1.98
    piperazine
    2 2-[4-(2-adamantyl)piperazin-1-yl]nicotinonitrile 323.2 2.01
    3 2-(4-norbornan-2-ylpiperazin-1-yl)-6- 351.2 2.17
    (trifluoromethyl)nicotinonitrile
    4 2-[1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-piperidyl]-4,6- 330.2 2.22
    dimethoxy-pyrimidine
    5 1-(3-nitro-2-pyridyl)-4-norbornan-2-yl-piperazine 303.2 1.74
    6 2-[4-(5-bicyclo[2.2.1]hept-2-enylmethyl)piperazin-1- 313.2 0.61
    yl]nicotinamide
    7 1-(3-chloro-2-pyridyl)-4-norbornan-2-yl-piperazine 291.9 2.06
    8 2-[4-(norbornan-2-ylmethyl)piperazin-1-yl]-6- 365.1 2.41
    (trifluoromethyl)nicotinonitrile
    9 1-[1-(3-bicyclo[3.2.1]octyl)-4-piperidyl]-1H-benzotriazole 311.2 2.15
    10 2-(4-norbornan-2-ylpiperazin-1-yl)nicotinamide 301.4 0.47
    11 3-[4-(4-cyano-6-phenyl-pyridazin-3-yl)piperazin-1-yl]-8- 447.4 2.19
    azabicyclo[3.2.1]octane-8-carboxylic acid ethyl ester
    12 3-[4-(3-cyano-2-pyridyl)piperazin-1-yl]-8- 370.2 1.8
    azabicyclo[3.2.1]octane-8-carboxylic acid ethyl ester
    13 6-[4-(5-bicyclo[2.2.1]hept-2-enylmethyl)piperazin-1- 295 2.12
    yl]nicotinonitrile
    14 6-[4-(norbornan-2-ylmethyl)piperazin-1-yl]nicotinamide 315.3 1.56
    15 1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-(6-methyl-2- 284.2 0.85
    pyridyl)-piperazine
    16 3-[4-(5-bicyclo[2.2.1]hept-2-enylmethyl)piperazin-1-yl]-2,5- 299.2 1.79
    dimethyl-pyrazine
    17 2-[4-(5-bicyclo[2.2.1]hept-2-enylmethyl)piperazin-1-yl]-3- 285.2 1.76
    methyl-pyrazine
    18 1-norbornan-2-yl-4-(4-pyridyl)piperazine 258.2 0.38
    19 6-(4-norbornan-2-ylpiperazin-1-yl)nicotinonitrile 283 1.6
    20 2-[4-(5-bicyclo[2.2.1]hept-2-enylmethyl)piperazin-1-yl]-3-
    methyl-pyridine
    21 1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-(6-chloro-2-pyridyl)- 304 2.47
    piperazine
    22 5-ethyl-2-[4-(norbornan-2-ylmethyl)piperazin-1-yl]- 301.5 2.2
    pyrimidine
    23 3-[4-(4-bicyclo[3.2.1]octylmethyl)piperazin-1-yl]pyrazine-2- 311.2 2.91
    carbonitrile
    24 3-[4-[3-cyano-6-(trifluoromethyl)-2-pyridyl]piperazin-1-yl]-8- 438.5 2.17
    azabicyclo[3.2.1]octane-8-carboxylic acid ethyl ester
    25 3-[4-(4-pyridyl)piperazin-1-yl]-8-azabicyclo[3.2.1]octane-8- 345.2 0.73
    carboxylic acid ethyl ester
    26 1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-(3,5-dichloro-4- 338.2 2.3
    pyridyl)-piperazine
    27 2-[4-(3-bicyclo[3.2.1]octyl)piperazin-1-yl]nicotinonitrile 297.2 1.86
    28 3-[4-[5-(trifluoromethyl)-2-pyridyl]piperazin-1-yl]-8- 413 2.34
    azabicyclo[3.2.1]octane-8-carboxylic acid ethyl ester
    29 3-[4-(1H-benzotriazol-1-yl)-1-piperidyl]-8- 384.2 1.97
    azabicyclo[3.2.1]octane-8-carboxylic acid ethyl ester
    30 3-[4-(3-fluoro-2-pyridyl)piperazin-1-yl]-8- 363.3 1.82
    azabicyclo[3.2.1]octane-8-carboxylic acid ethyl ester
    31 6-methyl-2-(4-norbornan-2-ylpiperazin-1-yl)-nicotinonitrile 297.2 1.88
    32 2-(4-norbornan-2-ylpiperazin-1-yl)nicotinonitrile 283.2 1.63
    33 3-[4-(3-cyano-5-phenyl-2-pyridyl)piperazin-1-yl]-8- 446.3 2.42
    azabicyclo[3.2.1]octane-8-carboxylic acid ethyl ester
    34 6-[4-(5-bicyclo[2.2.1]hept-2-enylmethyl)piperazin-1- 295 2.21
    yl]nicotinonitrile
    35 1-(3-bicyclo[3.2.1]octyl)-4-(4-pyridyl)piperazine 272.2 1.7
    36 3-[4-(5-carbamoyl-2-pyridyl)piperazin-1-yl]-8- 388.5 1.41
    azabicyclo[3.2.1]octane-8-carboxylic acid ethyl ester
    37 1-[1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-piperidyl]-1H- 309.4 1.88
    benzotriazole
    38 3-[[4-(3-cyanopyrazin-2-yl)piperazin-1-yl]methyl]-8- 384.23 1.98
    azabicyclo[3.2.1]octane-8-carboxylic acid ethyl ester
    39 2-[4-(5-bicyclo[2.2.1]hept-2-enylmethyl)piperazin-1- 271.3 1.84
    yl]pyrazine
    40 2,5-dimethyl-3-(4-norbornan-2-ylpiperazin-1-yl)-pyrazine 287 1.48
    41 1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-(4-pyridyl)piperazine 270.2 0.51
    42 2-[4-(5-bicyclo[2.2.1]hept-2-enylmethyl)piperazin-1- 295.2 1.85
    yl]nicotinonitrile
    43 3-(4-norbornan-2-ylpiperazin-1-yl)pyrazine-2-carbonitrile 284.4 1.44
    44 2-(4-norbornan-2-ylpiperazin-1-yl)pyrazine 259.1 0.88
    45 3-[4-(3-cyanopyrazin-2-yl)piperazin-1-yl]-8- 413 2.34
    azabicyclo[3.2.1]octane-8-carboxylic acid ethyl ester
    46 2-[4-(norbornan-2-ylmethyl)piperazin-1-yl]-5-phenyl- 373.1 2.58
    nicotinonitrile
    47 1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-[5-(trifluoromethyl)- 338.2 2.46
    2-pyridyl]-piperazine
    48 1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-(2-pyridyl)piperazine 270.3 0.8
    49 3-[4-(3-sulfamoyl-4-pyridyl)piperazin-1-yl]-8- 424.3 1.56
    azabicyclo[3.2.1]octane-8-carboxylic acid ethyl ester
    50 1-(1-norbornan-2-yl-4-piperidyl)-1H-benzotriazole 297 1.69
    51 3-[4-(5-acetyl-2-pyridyl)piperazin-1-yl]-8- 387.3 1.78
    azabicyclo[3.2.1]octane-8-carboxylic acid ethyl ester
    52 1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-(3-chloro-2-pyridyl)- 303.9 2.34
    piperazine
    53 2-[4-(5-bicyclo[2.2.1]hept-2-enylmethyl)piperazin-1-yl]-6- 363.2 2.35
    (trifluoromethyl)nicotinonitrile
    54 2-[1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4- 294.2 2.11
    piperidyl]nicotinonitrile
    55 4-[4-(norbornan-2-ylmethyl)piperazin-1-yl]pyridine-3- 351.3 1.67
    sulfonamide
    56 3-[4-(4-cyano-2-pyridyl)piperazin-1-yl]-8- 370.2 1.74
    azabicyclo[3.2.1]octane-8-carboxylic acid ethyl ester
    57 3-[4-(4,6-dimethoxypyrimidin-2-yl)-1-piperidyl]-8- 405.2 2.16
    azabicyclo[3.2.1]octane-8-carboxylic acid ethyl ester
    58 3-[4-[6-chloro-3-cyano-4-(trifluoromethyl)-2- 472.4 2.36
    pyridyl]piperazin-1-yl]-8-azabicyclo[3.2.1]octane-8-
    carboxylic acid ethyl ester
    59 3-[4-(norbornan-2-ylmethyl)piperazin-1-yl]-6-phenyl- 374.3 2.42
    pyridazine-4-carbonitrile
    60 1-(3-methyl-2-pyridyl)-4-norbornan-2-yl-piperazine 272.2 0.72
    61 1-(2-bicyclo[3.2.1]octyl)-4-(4-pyridyl)piperazine 272.2 1.49
    62 2-[4-(5-bicyclo[2.2.1]hept-2-enylmethyl)piperazin-1-yl]-6- 309.4 2.09
    methyl-nicotinonitrile
    63 2-methyl-3-(4-norbornan-2-ylpiperazin-1-yl)-pyrazine 273.2 1.28
    64 2-[4-(4-bicyclo[3.2.1]octylmethyl)piperazin-1- 310.216 2.39
    yl]nicotinonitrile
    65 1-norbornan-2-yl-4-(2-pyridyl)piperazine 258.3 0.46
    66 3-[4-(5-cyano-2-pyridyl)piperazin-1-yl]-8- 370 1.82
    azabicyclo[3.2.1]octane-8-carboxylic acid ethyl ester
    67 3-[4-(5-ethylpyrimidin-2-yl)piperazin-1-yl]-8- 374.2 2
    azabicyclo[3.2.1]octane-8-carboxylic acid ethyl ester
    68 3-[[4-(3-cyano-2-pyridyl)piperazin-1-yl]methyl]-8- 383.23 1.86
    azabicyclo[3.2.1]octane-8-carboxylic acid ethyl ester
    69 1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-[3-(trifluoromethyl)- 338.4 2.19
    2-pyridyl]-piperazine
    70 3-[4-(5-bicyclo[2.2.1]hept-2-enylmethyl)piperazin-1- 296.2 1.77
    yl]pyrazine-2-carbonitrile
    71 2-(4-norbornan-2-ylpiperazin-1-yl)pyrimidine 259.1 0.94
    72 4,6-dimethyl-2-(4-norbornan-2-ylpiperazin-1-yl)-pyrimidine 287.2 1.57
    73 6-methyl-2-[4-(norbornan-2-ylmethyl)piperazin-1-yl]-5- 387.3 2.71
    phenyl-nicotinonitrile
    74 1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-[3-chloro-5- 372.2 2.43
    (trifluoromethyl)-2-pyridyl]-piperazine
    75 1-(2-adamantyl)-4-(4-pyridyl)piperazine 298.2 0.61
    76 2-[4-(5-bicyclo[2.2.1]hept-2-enylmethyl)piperazin-1- 271.3 1.97
    yl]pyrimidine
    77 1-(6-methyl-2-pyridyl)-4-norbornan-2-yl-piperazine 272.2 0.45
    78 3-[4-(3-cyano-4,6-dimethyl-2-pyridyl)piperazin-1-yl]-8- 398.2 2.25
    azabicyclo[3.2.1]octane-8-carboxylic acid ethyl ester
    • Example 5 Functional Mobilization of Intracellular Calcium to Determine Muscarinic Receptor Activity
  • CHO cells expressing muscarinic receptors (M1 to M5) are grown as monolayers in tissue culture flasks at 37° C. in a humidified atmosphere containing 5% CO2 and passaged every 3-5 days. The growth media is Dulbecco's modified eagles medium (DMEM, Gibco Cat# 12430-054), containing 25 mM Hepes and supplemented with Fetal Bovine Serum (Hyclone, cat# SH30071.03), 0.1 mM of MEM non-essential amino acids (GIBCO, Cat# 11140-050), 1 mM MEM Sodium Pyruvate (GIBCO Cat# 11360-070) and 100 units/ml of Penicillin G and 100 μg/ml of Streptomycin (GIBCO Cat# 15140-122). The recombinant muscarinic receptor cell lines are grown under antibiotic pressure with media containing 25 μg/ml zeocin and 500 μg/ml G418 (M1-CHO), 4 μg/ml puromycin, 50 μg/ml zeocin and 2.5 μg/ml blasticidin (M2 and M4-CHO) or 50 μg/ml zeocin and 4 μg/ml puromycin (M3 and M5-CHO).
  • Cells are harvested at 80-90% confluence using Versene (GIBCO Cat# 15040-066), collected by centrifugation and seeded 18-24 hrs prior to running the calcium assay at a density of 5,000-10,000 cells/well in back-walled, clear-bottomed 384-well plates (BD Biocoat, poly-D-lysine, Cat#356663). The day of the experiment, the cells are washed with a plate washer (Bioteck Instruments, ELX 405) using bath1 buffer (140-mM NaCl, 4.5-mM KCl, 2-mM CaCl2, 1-mM MgCl2, 10-mM Hepes-Na, 10-mM Glucose, pH 7.4, with NaOH) containing 1 mM Probenecid. Next, the calcium dye Fluo-3 (25 μl/well of Fluo-3 AM at 4 μM, Molecular Probes F-1241, in Bath 1 buffer containing 1 mM Probenecid) is added to the 25 μl of Bath 1 remaining in each well after the plate wash and the dye is loaded at 37° C. in the tissue culture incubator for 60-90 min. The fluorescent dye is removed using the plate washer with Bath 1 containing 1 mM Probenecid, leaving 25 μl/well of this solution after the wash. Alternatively, cells can be loaded with the calcium indicator from Molecular Devices (Calcium 3 Assay Reagents, Cat # R7181) adding 5 μl of a 5× solution dye in Bath 1 containing 1 mM Probenecid (10 ml per dye flask cat# R7182 to generate a solution 20×) to 20 μl of the same buffer. After loading for 60 min, the experiment can be run without having to remove the dye.
  • Compounds are prepared at a 2× fold concentration in a 96-well plate (round bottom, Costar Corning cat# 3656), by reconstituting the pre-spotted compounds in bath 1 containing 1 mM probenecid. The final concentration DMSO is 0.5%, and the amount of DMSO is normalized across the assay plate. To determine an agonist action of the compounds on muscarinic receptors, the reconstituted compounds are added (25 μl compound/well) to the cell assay plate (containing 25 μl/well) using the multi-channel robotic system of the FLIPR 3 Instrument (Molecular Devices, Sunnyvale, Calif.). To determine a functional inhibitory action of the compounds on muscarinic receptors, the reconstituted compounds are added (25 μl compound/well) to the assay plate and pre-incubated for 15 min prior to adding 25 μl of Carbachol at 3× the EC80 for each muscarinic subtype. Alternatively, the compounds can be co-applied simultaneously with the agonist. In both assay modes, the fluorescence is recorded for 60 sec (excitation wavelength is 488 nM and emission wavelength 540 nm) using the FLIPR 3 instrument.
  • The potency, efficacy and selectivity of the muscarinic compounds were evaluated by screening the compound activity across the whole family (M1 to M5 cells).
  • The compounds of the present invention were found to selectively modulate the muscarinic receptors selectively over the other receptor types.
    • Example 6 β-Lactamase Assay to Determine Muscarinic Receptor Activity
  • CHO cells expressing muscarinic receptors (M1 to M5) and containing a gene reporter system β-Lactamase) with transcriptional control mediated by calcium release (NFAT activation). See Zlokarnik, G; Negulescu, P. A.; Knapp, T. E.; Mere, L; Burres, N; Feng, L; Whitney, M; Roemer, K; Tsien, R. Y. Quantitation of transcription and clonal selection of single living cells with β-lactamase as reporter. Science, 1998 Jan. 2, 279(5347):84-8. The cells are grown as monolayers in tissue culture flasks at 37° C. in a humidified atmosphere containing 5% CO2 and passaged every 3-5 days. The growth media is Dulbecco's modified eagles medium (DMEM, Gibco Cat# 12430-054), containing 25 mM Hepes and supplemented with 10% Fetal Bovine Serum (Hyclone, cat# SH30071.03), 0.1 mM of MEM non-essential amino acids (GIBCO, Cat# 11140-050), 1 mM MEM Sodium Pyruvate (GIBCO Cat# 11360-070) and 100 units/ml of Penicillin G and 100 μg/ml of Streptomycin (GIBCO Cat# 15140-122). The recombinant muscarinic receptor cell lines are grown under antibiotic pressure with media containing 25 μg/ml zeocin and 500 μg/ml G418 (M1-CHO), 4 μg/ml puromycin, 50 μg/ml zeocin and 2.5 μg/ml blasticidin (M2 and M4-CHO) or 50 μg/ml zeocin and 4 μg/ml puromycin (M3 and M5-CHO).
  • Cells are harvested at 80-90% confluence using Accutase (Innovative Cell Technologies, Inc. Cat# AT104), collected by centrifugation and seeded for 2-6 hours at a density of 15,000-20,000 cells/well in black-walled, clear-bottomed 384-well plates (BD Biocoat, poly-D-lysine, Cat#356663). Media is replaced with DMEM+1% Fetal Bovine Serum and incubated for another 12-18 hrs prior to running the β-Lactamase assay. The day of the experiment, compounds are prepared at a 1× fold concentration in a 96-well plate (round bottom, Costar Corning cat# 3656), by reconstituting the pre-spotted compounds in DMEM+1% FBS. The final concentration of DMSO is 0.5%, and the amount of DMSO is normalized across the assay plate. To determine an agonist action of the compounds on muscarinic receptors, the reconstituted compounds are added (25 μl compound/well) to the cell assay plate (where the media has been removed) using the multi-channel robotic system, Multimek 96 (Beckman). The compounds are incubated with the cells for 3 hours at 37° C., 5% CO2. to allow for expression of the reporter gene β-Lactamase.
  • After 3 hours, 5 μl of 6× fold concentrated CCF2/AM dye are added to the assay plates and incubated at room temperature for 1 hour. Fluorescent emission at two wavelengths (460 nm and 530 nm) is determined using the CytoFluor Series 4000 (PerSeptive Biosystems) and the calculations for reporter gene expression determined as specified in prior publications {Zlokarnik, G; Negulescu, P.A.; Knapp, T. E.; Mere, L; Burres, N; Feng, L; Whitney, M; Roemer, K; Tsien, R. Y. Quantitation of transcription and clonal selection of single living cells with β-lactamase as reporter. Science, 1998 Jan. 2, 279(5347):84-8.}
  • The potency, efficacy and selectivity of the muscarinic compounds were evaluated by screening the compound activity across the whole family (M1 to M5 cells). Compounds were also screened for activity on other proteins such as other GPCRs and ion channels to determine selectivity on M4 receptors.
  • The compounds of the present invention were found to modulate the muscarinic receptors selectively over the other receptor types.
  • Table 3 contains activity data for the compounds listed in Tables 1 and 2. The symbol “+++” refers to compounds which exhibited muscarinic modulation activity for at least one muscarinic receptor, M1, M2, M3, M4, at a concentration of less than 5 μM. The symbol “++” refers to compounds which exhibited muscarinic modulation activity for at least one muscarinic receptor, M1, M2, M3, M4, at a concentration of between 30 μM and 5 μM. The symbol “+” refers to compounds which exhibited muscarinic modulation activity for at least one muscarinic receptor, M1, M2, M3, M4, at a concentration of greater than 30 μM. The symbol “−” refers to compounds which were not assayed or did not exhibit muscarinic modulation activity for at least one muscarinic receptor, M1, M2, M3, M4, at the concentration at which the assay was performed.
  • TABLE 3
    No. ACTIVITY
    1 ++
    2 ++
    3 +
    4 +++
    5 +
    6 −
    7 +++
    8 −
    9 −
    10 −
    11 +
    12 +++
    13 +++
    14 −
    15 ++
    16 +++
    17 +++
    18 ++
    19 ++
    20 +++
    21 −
    22 −
    23 −
    24 +++
    25 +++
    26 −
    27 +
    28 +++
    29 +++
    30 +++
    31 ++
    32 +
    33 +
    34 +++
    35 ++
    36 +++
    37 +
    38 +++
    39 +
    40 −
    41 +++
    42 +++
    43 −
    44 ++
    45 +
    46 ++
    47 +
    48 ++
    49 +++
    50 ++
    51 +++
    52 ++
    53 +
    54 +++
    55 ++
    56 +++
    57 +++
    58 −
    59 +
    60 +
    61 −
    62 +++
    63 +
    64 +
    65 ++
    66 +++
    67 +++
    68 +++
    69 +++
    70 +++
    71 ++
    72 −
    73 −
    74 −
    75 ++
    76 +++
    77 −
    78 ++

Claims (41)

1. A method of modulating activity of a muscarinic receptor, comprising the step of contacting said receptor with a compound of formula (IV):
Figure US20100105693A1-20100429-C00024
or a pharmaceutically acceptable salt thereof,
wherein
AIV is adamantanyl, adamantanylmethyl, or
Figure US20100105693A1-20100429-C00025
Bond r is a single or double bond;
Each X1 is independently selected from CH2, CH2—CH2, or NR400,
Each W1 is independently selected from a bond, —(CH2)i—, —(CH2)iNRiC(O)—, —(CH2)iC(O)NRi—, —(CH2)iNRiSO2—, —(CH2)iSO2NRi—, C(O), O, S, NH, or S(O)2;
Ri is H or R2;
R2 is aliphatic, wherein each R2 optionally includes 1 to 2 substituents independently selected from R100, R4, or R5;
R4 is OR5, OR6, S(O)R6, S(O)R5, SO2R6, SO2R5, SO2N(R6)2, SO2N(R5)2, SO2NR5R6, SO3R6, SO3R5, C(O)R5, C(O)OR5, C(O)R6, C(O)OR6, C(O)N(R6)2, C(O)N(R5)2, C(O)N(R5R6), C(O)N(OR6)R6, C(O)N(OR5)R6, C(O)N(OR6)R5, C(O)N(OR5)R5, C(NOR6)R6, C(NOR6)R5, C(NOR5)R6, C(NOR5)R5, NR5C(O)R5, NR6C(O)R6, NR6C(O)R5, NR6C(O)OR6, NR5C(O)OR6, NR6C(O)OR5, NR5C(O)OR5, NR6C(O)N(R6)2, NR6C(O)NR5R6, NR6C(O)N(R5)2, NR5C(O)N(R6)2, NR5C(O)NR5R6, NR5C(O)N(R5)2, NR6SO2R6, NR6SO2R5, NR5SO2R5, NR6SO2N(R6)2, NR6SO2NR5R6, NR6SO2N(R5)2, NR5SO2NR5R6, NR5SO2N(R5)2, N(OR6)R6, N(OR6)R5, N(OR5)R5, or N(OR5)R6;
Each R5 is independently a cycloaliphatic, aryl, heterocyclic, or heteroaryl ring, each optionally including 1 to 3 R100 substituents;
Each R6 is independently H or aliphatic optionally substituted with R7;
Each R7 is independently a cycloaliphatic, aryl, heterocyclic, or heteroaryl ring, each optionally substituted with up to 2 substituents independently selected from H, (C1-C6)-straight or branched alkyl, (C2-C6) straight or branched alkenyl or alkynyl, 1,2-methylenedioxy, 1,2-ethylenedioxy, or (CH2)n—Z;
Each R8 is independently selected from R2, R3, or R4 or a protecting group.
Each Z is independently selected from halo, —CN, —NO2, —CF3, —OCF3, —OH, —S-aliphatic, —S(O)-aliphatic, —SO2-aliphatic, —COOH, —C(O)O(-aliphatic), or —O-aliphatic;
G is N or C(H);
C is
Figure US20100105693A1-20100429-C00026
in which the benzotriazole is optional substituted with 1-3 of R100, R2, R4, R5, or R6;
Each Z1 and Z3 is independently —N═, —C(H)═, or —C(R100)═;
Each Z2 is independently a carbon atom;
Each Z4 and Z6 is independently —N═, —C(H)═ or —C(R100)═;
Each Z5 is independently —N═, —C(H)═, or —C(R200)═, provided
a) that at least one of Z1, Z3, and Z5 is —N═;
b) that no more than two of Z1, Z2, Z3, Z4, and Z5 are —N═;
c) that no more than three of Z1, Z3, Z4, Z5, and Z6 are other than —N═ or —C(H)═;
d) when Z4 or Z6 is —C(R100)═, that (i) one of Z1 and Z3 is —C(R100)═, (ii) Z5 is —C(R200)═, or (iii) both Z4 and Z6 are —C(R100)═;
Each R100 is independently is —((C1-C4)aliphatic)p-Y2;
Y2 is halo, —CN, —NO2, —CF3, —OCF3, —SR600, —S(O)R600, —SO2R600, —SO2NR600, —COOR600, —C(O)N(R600)2, or —OR600; or
Each R200 is independently R100 or phenyl optionally substituted with 1-3 halo, —CN, —NO2, —CF3, —OCF3, —OH;
Each R400 is independently OR5, OR6, S(O)R6, S(O)R5, SO2R6, SO2R5, SO2N(R6)2, SO2N(R5)2, SO2NR5R6, SO3R6, SO3R5, C(O)R5, C(O)OR5, C(O)R6, C(O)OR6, C(O)N(R6)2, C(O)N(R5)2, C(O)N(R5R6), C(O)N(OR6)R6, C(O)N(OR5)R6, C(O)N(OR6)R5, C(O)N(OR5)R5, C(NOR6)R6, C(NOR6)R5, C(NOR5)R6, and C(NOR5)R5;
Each R600 is independently H or aliphatic optionally substituted with 1-3 substituents selected from halo, —CN, —NO2, —CF3, —OCF3, or —OH;
Each x is independently 1 or 2;
Each i is 0, 1 2, or 3;
Each m is independently 1 or 2; and
Each p is independently 0 or 1.
2. The method according to claim 1, wherein AIV is selected from:
Figure US20100105693A1-20100429-C00027
3. The method according to claim 2, wherein AIV is (ia).
4. The method according to claim 3, wherein AIV is
Figure US20100105693A1-20100429-C00028
5. The method according to claim 4, wherein W1 is a bond or —CH2—.
6. The method according to claim 2, wherein AIV is (ib).
7. The method according to claim 6, wherein AIV is
Figure US20100105693A1-20100429-C00029
8. The method according to claim 7, wherein W1 is a bond or —CH2—.
9. The method according to claim 2, wherein AIV is (ic).
10. The method according to claim 2, wherein W1 is a bond or CH2.
11. The method according to claim 1, wherein W1 is a bond or CH2.
12. The method according to claim 1, wherein AIV is selected from:
Figure US20100105693A1-20100429-C00030
13. The method according to claim 12, wherein AIV is (iia).
14. The method according to claim 12, wherein AIV is (iib).
15. The method according to claim 12, wherein AIV is (iic).
16. The method according to claim 12, wherein W1 is a bond or CH2.
17. The method according to claim 1, wherein AIV is
Figure US20100105693A1-20100429-C00031
18. The method according to claim 17, wherein W1 is a bond or CH2.
19. The method according to claim 17, wherein AIV is
Figure US20100105693A1-20100429-C00032
20. The method according to claim 19, wherein W1 is a bond.
21. The method according to claim 17, wherein R6 is aliphatic optionally substituted with R7.
22. The method according to claim 21, wherein R6 is alkyl optionally substituted with R7.
23. The method according to claim 22, wherein R6 is alkyl.
24. The method according to claim 1, wherein AIV is adamantyl or adamantylmethyl.
25. The method according to claim 1, wherein ring C is
Figure US20100105693A1-20100429-C00033
26. The method according to claim 25, wherein Z1 is —N═.
27. The method according to claim 26, wherein Z3 is —N═.
28. The method according to claim 26, wherein Z3 is —C(R100)═.
29. The method according to claim 28, wherein R100 is halo, nitro, —CN, S(O)2NH2, —CF3, alkoxy, acyl, —C(O)NH2, or aliphatic.
30. The method according to claim 25, wherein Z4 is —N═.
31. The method according to claim 25, wherein Z5 is —N═.
32. The method according to claim 1, wherein ring C is selected from:
Figure US20100105693A1-20100429-C00034
33. The method according to claim 32, wherein each of C rings (a) through (j) are substituted with one R100 substituent ortho or para relative to the point of attachment between ring C and the piperazine or piperidine ring, or one R100 substituent ortho, meta, or para relative to the point of attachment between ring C and the piperazine or piperidine ring and one R100 substituent meta relative to the point of attachment between ring C and the piperazine or piperidine ring.
34. The method according to claim 33, wherein each R100 is independently halo, nitro, —CN, S(O)2NH2, —CF3, alkoxy, acyl, —C(O)NH2, or aliphatic.
35. The method according to claim 33, wherein ring C is 3-cyano-2-pyridyl or 5-cyano-2-pyridyl.
36. The method according to claim 1, wherein ring C is
Figure US20100105693A1-20100429-C00035
37. The method according to claim 36, wherein the benzotriazole is optionally substituted with 1-4 substituents selected from halo, cyano, C1-C4 alkyl, and CF3.
38. The method according to claim 1, wherein the compounds is
1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-(3-nitro-2-pyridyl)-piperazine;
2-[4-(2-adamantyl)piperazin-1-yl]nicotinonitrile;
2-(4-norbornan-2-ylpiperazin-1-yl)-6-(trifluoromethyl)nicotinonitrile;
2-[1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-piperidyl]-4,6-dimethoxy-pyrimidine;
1-(3-nitro-2-pyridyl)-4-norbornan-2-yl-piperazine;
2-[4-(5-bicyclo[2.2.1]hept-2-enylmethyl)piperazin-1-yl]nicotinamide;
1-(3-chloro-2-pyridyl)-4-norbornan-2-yl-piperazine;
2-[4-(norbornan-2-ylmethyl)piperazin-1-yl]-6-(trifluoromethyl)nicotinonitrile;
1-[1-(3-bicyclo[3.2.1]octyl)-4-piperidyl]-1H-benzotriazole;
2-(4-norbornan-2-ylpiperazin-1-yl)nicotinamide;
3-[4-(4-cyano-6-phenyl-pyridazin-3-yl)piperazin-1-yl]-8-azabicyclo[3.2.1]octane-8-carboxylic acid ethyl ester;
3-[4-(3-cyano-2-pyridyl)piperazin-1-yl]-8-azabicyclo[3.2.1]octane-8-carboxylic acid ethyl ester;
6-[4-(5-bicyclo[2.2.1]hept-2-enylmethyl)piperazin-1-yl]nicotinonitrile;
6-[4-(norbornan-2-ylmethyl)piperazin-1-yl]nicotinamide;
1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-(6-methyl-2-pyridyl)-piperazine;
3-[4-(5-bicyclo[2.2.1]hept-2-enylmethyl)piperazin-1-yl]-2,5-dimethyl-pyrazine;
2-[4-(5-bicyclo[2.2.1]hept-2-enylmethyl)piperazin-1-yl]-3-methyl-pyrazine;
1-norbornan-2-yl-4-(4-pyridyl)piperazine;
6-(4-norbornan-2-ylpiperazin-1-yl)nicotinonitrile;
2-[4-(5-bicyclo[2.2.1]hept-2-enylmethyl)piperazin-1-yl]-3-methyl-pyridine;
1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-(6-chloro-2-pyridyl)-piperazine;
5-ethyl-2-[4-(norbornan-2-ylmethyl)piperazin-1-yl]-pyrimidine;
3-[4-(4-bicyclo[3.2.1]octylmethyl)piperazin-1-yl]pyrazine-2-carbonitrile;
3-[4-[3-cyano-6-(trifluoromethyl)-2-pyridyl]piperazin-1-yl]-8-azabicyclo[3.2.1]octane-8-carboxylic acid ethyl ester;
3-[4-(4-pyridyl)piperazin-1-yl]-8-azabicyclo[3.2.1]octane-8-carboxylic acid ethyl ester;
1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-(3,5-dichloro-4-pyridyl)-piperazine;
2-[4-(3-bicyclo[3.2.1]octyl)piperazin-1-yl]nicotinonitrile;
3-[4-[5-(trifluoromethyl)-2-pyridyl]piperazin-1-yl]-8-azabicyclo[3.2.1]octane-8-carboxylic acid ethyl ester;
3-[4-(1H-benzotriazol-1-yl)-1-piperidyl]-8-azabicyclo[3.2.1]octane-8-carboxylic acid ethyl ester;
3-[4-(3-fluoro-2-pyridyl)piperazin-1-yl]-8-azabicyclo[3.2.1]octane-8-carboxylic acid ethyl ester;
6-methyl-2-(4-norbornan-2-ylpiperazin-1-yl)-nicotinonitrile;
2-(4-norbornan-2-ylpiperazin-1-yl)nicotinonitrile;
3-[4-(3-cyano-5-phenyl-2-pyridyl)piperazin-1-yl]-8-azabicyclo[3.2.1]octane-8-carboxylic acid ethyl ester;
6-[4-(5-bicyclo[2.2.1]hept-2-enylmethyl)piperazin-1-yl]nicotinonitrile;
1-(3-bicyclo[3.2.1]octyl)-4-(4-pyridyl)piperazine;
3-[4-(5-carbamoyl-2-pyridyl)piperazin-1-yl]-8-azabicyclo[3.2.1]octane-8-carboxylic acid ethyl ester;
1-[1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-piperidyl]-1H-benzotriazole;
3-[[4-(3-cyanopyrazin-2-yl)piperazin-1-yl]methyl]-8-azabicyclo[3.2.1]octane-8-carboxylic acid ethyl ester;
2-[4-(5-bicyclo[2.2.1]hept-2-enylmethyl)piperazin-1-yl]pyrazine;
2,5-dimethyl-3-(4-norbornan-2-ylpiperazin-1-yl)-pyrazine;
1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-(4-pyridyl)piperazine;
2-[4-(5-bicyclo[2.2.1]hept-2-enylmethyl)piperazin-1-yl]nicotinonitrile;
3-(4-norbornan-2-ylpiperazin-1-yl)pyrazine-2-carbonitrile;
2-(4-norbornan-2-ylpiperazin-1-yl)pyrazine;
3-[4-(3-cyanopyrazin-2-ylpiperazin-1-yl]-8-azabicyclo[3.2.1]octane-8-carboxylic acid ethyl ester;
2-[4-(norbornan-2-ylmethyl)piperazin-1-yl]-5-phenyl-nicotinonitrile;
1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-[5-(trifluoromethyl)-2-pyridyl]-piperazine;
1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-(2-pyridyl)piperazine;
3-[4-(3-sulfamoyl-4-pyridyl)piperazin-1-yl]-8-azabicyclo[3.2.1]octane-8-carboxylic acid ethyl ester;
1-(1-norbornan-2-yl-4-piperidyl)-1H-benzotriazole;
3-[4-(5-acetyl-2-pyridyl)piperazin-1-yl]-8-azabicyclo[3.2.1]octane-8-carboxylic acid ethyl ester;
1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-(3-chloro-2-pyridyl)-piperazine;
2-[4-(5-bicyclo[2.2.1]hept-2-enylmethyl)piperazin-1-yl]-6-(trifluoromethyl)nicotinonitrile;
2-[1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-piperidyl]nicotinonitrile;
4-[4-(norbornan-2-ylmethyl)piperazin-1-yl]pyridine-3-sulfonamide;
3-[4-(4-cyano-2-pyridyl)piperazin-1-yl]-8-azabicyclo[3.2.1]octane-8-carboxylic acid ethyl ester;
3-[4-(4,6-dimethoxypyrimidin-2-yl)-1-piperidyl]-8-azabicyclo[3.2.1]octane-8-carboxylic acid ethyl ester;
3-[4-[6-chloro-3-cyano-4-(trifluoromethyl)-2-pyridyl]piperazin-1-yl]-8-azabicyclo[3.2.1]octane-8-carboxylic acid ethyl ester;
3-[4-(norbornan-2-ylmethyl)piperazin-1-yl]-6-phenyl-pyridazine-4-carbonitrile;
1-(3-methyl-2-pyridyl)-4-norbornan-2-yl-piperazine;
1-(2-bicyclo[3.2.1]octyl)-4-(4-pyridyl)piperazine;
2-[4-(5-bicyclo[2.2.1]hept-2-enylmethyl)piperazin-1-yl]-6-methyl-nicotinonitrile;
2-methyl-3-(4-norbornan-2-ylpiperazin-1-yl)-pyrazine;
2-[4-(4-bicyclo[3.2.1]octylmethyl)piperazin-1-yl]nicotinonitrile;
1-norbornan-2-yl-4-(2-pyridyl)piperazine;
3-[4-(5-cyano-2-pyridyl)piperazin-1-yl]-8-azabicyclo[3.2.1]octane-8-carboxylic acid ethyl ester;
3-[4-(5-ethylpyrimidin-2-ylpiperazin-1-yl]-8-azabicyclo[3.2.1]octane-8-carboxylic acid ethyl ester;
3-[[4-(3-cyano-2-pyridyl)piperazin-1-yl]methyl]-8-azabicyclo[3.2.1]octane-8-carboxylic acid ethyl ester;
1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-[3-(trifluoromethyl)-2-pyridyl]-piperazine;
3-[4-(5-bicyclo[2.2.1]hept-2-enylmethyl)piperazin-1-yl]pyrazine-2-carbonitrile;
2-(4-norbornan-2-ylpiperazin-1-yl)pyrimidine;
4,6-dimethyl-2-(4-norbornan-2-ylpiperazin-1-yl)-pyrimidine;
6-methyl-2-[4-(norbornan-2-ylmethyl)piperazin-1-yl]-5-phenyl-nicotinonitrile;
1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-[3-chloro-5-(trifluoromethyl)-2-pyridyl]-piperazine;
1-(2-adamantyl)-4-(4-pyridyl)piperazine;
2-[4-(5-bicyclo[2.2.1]hept-2-enylmethyl)piperazin-1-yl]pyrimidine;
1-(6-methyl-2-pyridyl)-4-norbornan-2-yl-piperazine; or
3-[4-(3-cyano-4,6-dimethyl-2-pyridyl)piperazin-1-yl]-8-azabicyclo[3.2.1]octane-8-carboxylic acid ethyl ester.
39. The method according to claim 1, wherein said muscarinic receptor is M1.
40. The method according to claim 1, wherein said muscarinic receptor is M4.
41. The method according to claim 1, wherein the compounds modulate M1 and M4 muscarinic receptors more than M2 and M3 muscarinic receptors.
US12/652,357 2004-05-28 2010-01-05 Modulators of Muscarinic Receptors Abandoned US20100105693A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/652,357 US20100105693A1 (en) 2004-05-28 2010-01-05 Modulators of Muscarinic Receptors

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US57523304P 2004-05-28 2004-05-28
US11/140,808 US7820817B2 (en) 2004-05-28 2005-05-31 Modulators of muscarinic receptors
USPCT/US05/18900 2005-05-31
PCT/US2005/018900 WO2005117883A1 (en) 2004-05-28 2005-05-31 Modulators of muscarinic receptors
US12/652,357 US20100105693A1 (en) 2004-05-28 2010-01-05 Modulators of Muscarinic Receptors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/140,808 Division US7820817B2 (en) 2004-05-28 2005-05-31 Modulators of muscarinic receptors

Publications (1)

Publication Number Publication Date
US20100105693A1 true US20100105693A1 (en) 2010-04-29

Family

ID=34971455

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/140,808 Expired - Fee Related US7820817B2 (en) 2004-05-28 2005-05-31 Modulators of muscarinic receptors
US12/652,357 Abandoned US20100105693A1 (en) 2004-05-28 2010-01-05 Modulators of Muscarinic Receptors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US11/140,808 Expired - Fee Related US7820817B2 (en) 2004-05-28 2005-05-31 Modulators of muscarinic receptors

Country Status (12)

Country Link
US (2) US7820817B2 (en)
EP (1) EP1753429A1 (en)
JP (1) JP2008501031A (en)
KR (1) KR20070034524A (en)
CN (1) CN101005842A (en)
AU (1) AU2005249494A1 (en)
CA (1) CA2568524A1 (en)
IL (1) IL179526A0 (en)
MX (1) MXPA06013842A (en)
RU (1) RU2006146985A (en)
WO (1) WO2005117883A1 (en)
ZA (1) ZA200609893B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9643957B2 (en) 2012-12-11 2017-05-09 Takeda Pharmaceutical Company Limited Heterocyclic compounds having cholesterol 24-hydroxylase activity

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6374762B1 (en) * 1997-10-27 2002-04-23 Correct Craft, Inc. Water sport towing apparatus
UY28538A1 (en) * 2003-09-26 2005-04-29 Vertex Pharma PHENYL-PIPERAZINE DERIVATIVES AS MUSCARINIC RECEPTORS MODULATORS
RU2007109794A (en) 2004-08-19 2008-09-27 Вертекс Фармасьютикалз, Инкорпорейтед (Us) MUSCARINE RECEPTOR MODULATORS
US7786141B2 (en) * 2004-08-19 2010-08-31 Vertex Pharmaceuticals Incorporated Dihydrospiroindene modulators of muscarinic receptors
RU2007124373A (en) * 2004-11-29 2009-01-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) MUSCARINE RECEPTION MODULATORS
BRPI0613564A2 (en) 2005-07-04 2011-01-18 Novo Nordisk As compounds, their uses in the preparation of pharmaceutical compositions and pharmaceutical compositions comprising the same
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Fast Dissociting Dopamine 2 Receptor Antagonists
WO2007076070A2 (en) * 2005-12-22 2007-07-05 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
ATE517106T1 (en) 2006-02-22 2011-08-15 Vertex Pharma CONDENSED SPIROPIPERIDINE AS MODULATORS OF MUSCARINOUS RECEPTORS
WO2007100664A2 (en) * 2006-02-22 2007-09-07 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
EP2035407A1 (en) * 2006-06-09 2009-03-18 AstraZeneca AB Muscarinic receptor agonists that are effective in the treatment of pain, alzheimer's disease and schizophrenia
TW200815405A (en) * 2006-06-09 2008-04-01 Astrazeneca Ab Novel compounds
TW200813018A (en) * 2006-06-09 2008-03-16 Astrazeneca Ab Novel compounds
EP2051712A2 (en) * 2006-08-15 2009-04-29 Vertex Pharmceuticals Incorporated Modulators of muscarinic receptors
AU2007284350A1 (en) 2006-08-18 2008-02-21 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
JO2642B1 (en) 2006-12-08 2012-06-17 جانسين فارماسوتيكا ان. في Fast Dissociating Dopamine 2 Receptor Antagonists
JO2849B1 (en) * 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Fast -Dissociating Dopamine 2 Receptor Antagonists
KR101506156B1 (en) 2007-04-23 2015-03-26 얀센 파마슈티카 엔.브이. Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists
AU2008240728B2 (en) 2007-04-23 2013-01-10 Janssen Pharmaceutica N.V. 4-alkoxypyridazine derivatives as fast dissociating dopamine 2 receptor antagonists
US8119661B2 (en) 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
EP2207549A1 (en) * 2007-10-03 2010-07-21 Vertex Pharmceuticals Incorporated Modulators of muscarinic receptors
US7910588B2 (en) 2007-10-12 2011-03-22 Eli Lilly And Company 5-HT7 receptor antagonists
JP5524491B2 (en) * 2008-03-04 2014-06-18 石原産業株式会社 Method for producing 3-amino-2-chloro-6-trifluoromethylpyridine
ES2344040B1 (en) 2008-04-24 2011-06-20 Zobele España, S.A EVAPORATOR OF VOLATILE SUBSTANCES WITH END OF LIFE DETECTOR OF THE SUBSTANCE.
BRPI0915834A2 (en) 2008-07-03 2015-11-03 Janssen Pharmaceutica Nv Substituted 6- (1-piperazinyl) -pyridazines as 5-ht6 receptor antagonists
DK2307374T3 (en) 2008-07-31 2017-05-01 Janssen Pharmaceutica Nv PIPERAZIN-1-YLTRIFLUORMETHYL-SUBSTITUTED PYRIDINES AS QUICK DISSOCATING DOPAMIN-2 RECEPTOR ANTAGONISTS
US8697691B2 (en) 2009-12-21 2014-04-15 Vanderbilt University Alkyl 3-((2-amidoethyl)amino)-8-azabicyclo[3.2.1]octane-8-carboxylate analogs as selective M1 agonists and methods of making and using same
SI2531492T1 (en) 2010-02-05 2016-08-31 Heptares Therapeutics Limited 1,2,4-triazine-4-amine derivatives
WO2011112825A2 (en) * 2010-03-10 2011-09-15 Vanderbilt University Heterocyclyl-azabicyclo[3.2.1]octane analogs as selective m1 agonists and methods of making and using same
EP2661421A2 (en) * 2011-01-07 2013-11-13 Targacept, Inc. Nicotinic receptor non-competitive antagonists
ES2602039T3 (en) * 2012-09-18 2017-02-17 Heptares Therapeutics Limited Bicyclic aza compounds as muscarinic M1 receptor agonists
WO2014122474A1 (en) 2013-02-07 2014-08-14 Takeda Pharmaceutical Company Limited Piperidin-1 -yl and azepin-1 -yl carboxylates as muscarinic m4 receptor agonists
PT3102568T (en) 2014-02-06 2018-10-24 Heptares Therapeutics Ltd Bicyclic aza compounds as muscarinic m1 receptor agonists.
EP3122356B1 (en) 2014-04-10 2020-06-03 Dalhousie University Treatment of parkinson's disease through arfgap1 inhibition
DK3768669T3 (en) * 2018-03-23 2023-04-24 Pfizer Piperazinazaspiro derivatives

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7490177B2 (en) * 2006-01-23 2009-02-10 Infineon Technologies Ag System method for performing a direct memory access for automatically copying initialization boot code in a new memory architecture
US7613913B2 (en) * 2006-03-21 2009-11-03 Silicon Laboratories Inc. Digital architecture using one-time programmable (OTP) memory

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3354161A (en) * 1964-07-16 1967-11-21 Miles Lab 8alpha-(4-phenyl-1-piperazyl)-4alpha, 5, 6, 7, 8alpha-hexahydro-4h-1-benzopyrans and process
WO1996014297A1 (en) 1994-11-04 1996-05-17 Sumitomo Pharmaceuticals Company, Limited Novel lactam derivatives
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
CA2338804A1 (en) 1998-07-28 2000-02-10 Smithkline Beecham Corporation Propenamides as ccr5 modulators
CA2343536A1 (en) 1998-09-04 2000-03-16 Yoshisuke Nakasato Chemokine receptor antagonists and methods of use therefor
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
JP2002535256A (en) 1999-01-25 2002-10-22 スミスクライン・ビーチャム・コーポレイション Compounds and methods
US20040229908A1 (en) 1999-07-13 2004-11-18 Jodi Nelson Compositions and methods for the treatment of Parkinson's disease and tardive dyskinesias
US7115750B1 (en) 1999-09-20 2006-10-03 Takeda Pharmaceutical Company Limited Melanin concentrating hormone antagonist
US20050074487A1 (en) 1999-12-16 2005-04-07 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
AU2001243394A1 (en) 2000-03-02 2001-09-12 Smith Kline Beecham Corporation Compounds and methods
US7342016B2 (en) 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
US20040137062A1 (en) 2001-05-25 2004-07-15 Sham Chopra Chronotherapy tablet and methods related thereto
US7572448B2 (en) 2002-07-15 2009-08-11 Board Of Regents, The University Of Texas System Combined cancer treatment methods using selected antibodies to aminophospholipids
US7384909B2 (en) 2002-07-15 2008-06-10 Board Of Regents, The University Of Texas System Anti-viral treatment methods using phosphatidylethanolamine-binding peptides linked to anti-viral agents
US7511124B2 (en) 2002-07-15 2009-03-31 Board Of Regents, The University Of Texas System Compositions comprising phosphatidylethanolamine-binding peptides linked to anti-viral agents
AU2003256922A1 (en) 2002-07-31 2004-02-16 Smithkline Beecham Corporation Substituted heterocyclic compounds as modulators of the ccr5 receptor
AU2003254177A1 (en) 2002-07-31 2004-02-16 Smithkline Beecham Corporation Substituted benzanilides as modulators of the ccr5 receptor
AU2003256923A1 (en) 2002-07-31 2004-02-16 Smithkline Beecham Corporation Substituted benzanilides as modulators of the ccr5 receptor
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7365221B2 (en) 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
US20050085463A1 (en) 2003-01-23 2005-04-21 Weiner David M. Use of N-desmethylclozapine to treat human neuropsychiatric disease
US7537765B2 (en) 2003-01-29 2009-05-26 Panacos Pharmaceuticals, Inc. Inhibition of HIV-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein
US20050026902A1 (en) 2003-01-31 2005-02-03 Timothy Maziasz Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents
WO2004069828A1 (en) * 2003-02-04 2004-08-19 Mitsubishi Pharma Corporation Piperidine compound and medicinal use thereof
US7034023B2 (en) 2003-04-04 2006-04-25 Pfizer Inc Pyrrolo[1,2-B]pyridazine compounds and their uses
EA009598B1 (en) 2003-05-16 2008-02-28 Синвеншн Аг Medical implants comprising biocompatible coatings
US8029822B2 (en) 2003-05-22 2011-10-04 Osmotica Kereskedelmi és Seolgáltató KFT Rupturing controlled release device having a preformed passageway
SI1626749T1 (en) 2003-05-28 2009-04-30 Cinv Ag Implants comprising functionalized carbon surfaces
WO2004112747A2 (en) 2003-06-24 2004-12-29 Baxter International Inc. Specific delivery of drugs to the brain
US20040265238A1 (en) 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
WO2005002597A1 (en) 2003-07-02 2005-01-13 Polycord, Inc. Method for delivering polymerized therapeutic agent compositions and compositions thereof
WO2005007656A1 (en) 2003-07-18 2005-01-27 Virochem Pharma Inc. Spiro compounds and methods for the modulation of chemokine receptor activity
US20050042177A1 (en) 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base
US20050032794A1 (en) 2003-08-05 2005-02-10 Padia Janak K. Diamine derivatives of quinone and uses thereof
US20050031713A1 (en) 2003-08-06 2005-02-10 Elliot Ehrich Methods for administering active agents to CYP3A4 sensitive patients
ATE415946T1 (en) 2003-08-08 2008-12-15 Elan Pharma Int Ltd NEW METAXALONE COMPOSITIONS
CA2536482C (en) 2003-08-25 2012-07-24 Foamix Ltd. Penetrating pharmaceutical foam
US7462618B2 (en) 2003-08-27 2008-12-09 Sun Health Research Institute Treatment of inflammatory autoimmune diseases with alpha-adrenergic antagonists and beta-adrenergic agonists
US20050055078A1 (en) 2003-09-04 2005-03-10 Medtronic Vascular, Inc. Stent with outer slough coating
US20050058696A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US20050059023A1 (en) 2003-09-16 2005-03-17 Cantor Thomas L. Methods and kits for monitoring resistance to therapeutic agents
AU2004203436A1 (en) 2003-09-24 2005-04-14 Bioxell Spa Compound and use in treatment
UY28538A1 (en) * 2003-09-26 2005-04-29 Vertex Pharma PHENYL-PIPERAZINE DERIVATIVES AS MUSCARINIC RECEPTORS MODULATORS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7490177B2 (en) * 2006-01-23 2009-02-10 Infineon Technologies Ag System method for performing a direct memory access for automatically copying initialization boot code in a new memory architecture
US7613913B2 (en) * 2006-03-21 2009-11-03 Silicon Laboratories Inc. Digital architecture using one-time programmable (OTP) memory

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9643957B2 (en) 2012-12-11 2017-05-09 Takeda Pharmaceutical Company Limited Heterocyclic compounds having cholesterol 24-hydroxylase activity
US10112956B2 (en) 2012-12-11 2018-10-30 Takeda Pharmaceutical Company Limited Heterocyclic compounds having cholesterol 24-hydroxylase activity

Also Published As

Publication number Publication date
WO2005117883A1 (en) 2005-12-15
CA2568524A1 (en) 2005-12-15
JP2008501031A (en) 2008-01-17
AU2005249494A1 (en) 2005-12-15
US20060019962A1 (en) 2006-01-26
RU2006146985A (en) 2008-07-10
US7820817B2 (en) 2010-10-26
MXPA06013842A (en) 2007-03-01
IL179526A0 (en) 2007-07-04
ZA200609893B (en) 2008-08-27
CN101005842A (en) 2007-07-25
KR20070034524A (en) 2007-03-28
EP1753429A1 (en) 2007-02-21

Similar Documents

Publication Publication Date Title
US7820817B2 (en) Modulators of muscarinic receptors
US20090042928A1 (en) Modulators of muscarinic receptors
JP6716711B2 (en) 6-Hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamide as APJ agonist
US20090239873A1 (en) Phenyl-piperazine derivatives as modulators of muscarinic receptors
TWI617552B (en) Compounds and methods for kinase modulation, and indications therefor
KR101985050B1 (en) Pyrazine carboxamide compound
TWI692472B (en) Therapeutically active compounds and their methods of use
KR102038462B1 (en) Use of inhibitors of the activity or function of PI3K
US8497295B2 (en) Spiroindoline modulators of muscarinic receptors
TW201625619A (en) Inhibiting the transient receptor potential A1 ion channel
JP2008163045A (en) Heterocyclic inhibitor of erk2 and use thereof
MX2010008421A (en) Compounds and compositions as kinase inhibitors.
JP2023545274A (en) Compounds and methods of treating cancer
EP2477492A1 (en) Substituted heteroarylamine carboxamide analogs as mglur5 negative allosteric modulators and methods of making and using the same
US20110294858A1 (en) Substituted 6-methylnicotinamides as mglur5 positive allosteric modulators
KR20060128950A (en) Amidopyrazole derivative
CN115605267A (en) Selective modulators of mutant LRRK2 proteolysis and related methods of use
KR20070063530A (en) 1,5-diheterocycle-1h-triazole derivative
US12024506B2 (en) Compounds
US20240270741A1 (en) Compounds for fgfrs inhibitors
WO2024059204A1 (en) Heteroaryl analogs as mglu5 negative allosteric modulators and methods of making and using the same
US20230080054A1 (en) Inhibitors of anoctamin 6 protein and uses thereof

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION